Heterocyclic compound acting as α5-gaba a receptor regulator

By developing heterocyclic compounds with α5-GABAA receptor inhibitory activity, the non-specific problem of α5-GABAA receptor modulators in the prior art has been solved, and efficient regulation and safe treatment of α5-GABAA receptors have been achieved, which is suitable for Treats a variety of cognitive and neurological diseases.

WO2024245156A1PCT designated stage expired Publication Date: 2024-12-05WUHAN HUMANWELL INNOVATIVE DRUG RES & DEV CENT LTD CO
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/095295
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-17
Filing Date
2024-05-24
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The existing α5-GABAA receptor modulators nonspecifically bind to multiple subunits of GABAA receptors, resulting in adverse reactions, and it is difficult to selectively and specifically regulate α5-GABAA receptors, affecting the therapeutic effect.

Method used

A new class of heterocyclic compounds with inhibitory activity of α5-GABAA receptors is developed to prepare drugs for the treatment of diseases associated with α5-GABAA receptors, improving drug selection through specific structural design and synthesis methods Sex and safety.

Benefits of technology

Effective regulation of α5-GABAA receptor has been achieved, significantly improving the effect of treating α5-GABAA receptor-mediated diseases, with excellent pharmacokinetic properties and high safety, suitable for the treatment of such as Alzheimer's disease , diseases such as polyinfarction dementia and stroke.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024095295_05122024_PF_FP_ABST
    Figure CN2024095295_05122024_PF_FP_ABST
Patent Text Reader

Abstract

A heterocyclic compound as shown in formula IA, and a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or a prodrug thereof. The compound has a regulatory function on a α5-GABAA receptor.
Need to check novelty before this filing date? Find Prior Art

Description

One as α5-GABA A Heterocyclic compounds as receptor modulators

[0001] The present invention claims:

[0002] The patent application number is 202310611467.9 and was filed with the State Intellectual Property Office of China on May 26, 2023, entitled “An α5-GABA A The priority right of the prior application for "Receptor modulators and uses thereof";

[0003] The patent application number is 202311371052.5 and was filed with the State Intellectual Property Office of China on October 20, 2023, entitled "An α5-GABA A The priority right of the prior application for "Receptor modulators and uses thereof";

[0004] The patent application number is 202410070306.8 and was filed with the State Intellectual Property Office of China on January 17, 2024. The name of the application is “An α5-GABA A The priority right of the prior application for "Receptor modulators and uses thereof";

[0005] Priority to the prior application, patent application number 202410624357.0, filed with the State Intellectual Property Office of China on May 17, 2024, entitled “A heterocyclic compound as an α5-GABAA receptor modulator”;

[0006] The entire contents of said prior application are incorporated herein by reference. Technical Field

[0007] The present invention belongs to the field of medicine, and in particular, it relates to a kind of α5-GABA A Heterocyclic compounds that are receptor modulators. Background Art

[0008] GABA A GABA receptors are associated with a variety of diseases and are possible therapeutic targets, which has also promoted the A Research on the physiological and pharmacological effects of different subunits of the receptor. For example, studies using genetically modified mice have shown that the most widely distributed α5 subunit of the γ-aminobutyric acid A receptor (α5-GABA A Benzodiazepine receptors α2-GABA is the main target of benzodiazepines (BDZ) drugs for their sedative and amnesic effects. A Receptors and α3-GABA A α5-GABA receptors are associated with the anticonvulsant and antianxiety effects of drugs.A The receptor is an inhibitory receptor in the central nervous system of mammals, mainly distributed in the hippocampus of the brain. It produces an inhibitory effect on hippocampal neurons by regulating the outward current of chloride ions. Its expression level in the cerebral cortex is very low and almost not expressed in other brain regions. The hippocampus is the main site for cognitive functions such as learning and memory, which indicates that α5-GABA A Receptors may be related to cognitive functions such as learning and memory. In addition to BDZ drugs, there are many other drugs such as propofol, etomidate, barbiturates and neurosteroids that can stimulate GABA A The allosteric regulatory sites of the receptor enhance the neural function of GABA, thereby producing corresponding pharmacological effects, which play an anesthetic, anxiolytic, sedative or anti-epileptic role in clinical practice. A The non-specific binding of multiple subunits of the receptor leads to many adverse reactions such as drug tolerance, sedation, anxiety or convulsions. Therefore, researchers have been committed to studying and discovering the specific A Drugs that have selective and specific effects on receptor subunits.

[0009] Numerous studies have shown that α5-GABA A Changes in receptor excitability can affect cognitive functions such as learning and memory, leading to the occurrence of some diseases such as postoperative cognitive dysfunction, pain, depression, schizophrenia, and Down syndrome. Allosteric modulators can treat or improve these diseases.

[0010] Considering α5-GABA A Many pharmaceutical companies, including Roche, are engaged in the study of the specific distribution and function of α5-GABA receptors in the hippocampus of the brain. A A large number of compounds have been synthesized in the research of receptor ligands, especially those targeting α5-GABA in the hippocampus of the brain. A Inverse agonists of GABA receptors, of which α5IA and MRK-016 have shown good effects in treating cognitive diseases in animal disease models and human trials, especially in treating Alzheimer's disease. A Receptor inverse agonists can be used to treat cognitive diseases, especially Alzheimer's disease. Patent application US20110224278A1 discloses a novel GABA-containing A Inverse agonists of the receptors may be used to treat multi-infarct dementia and stroke-related disorders.

[0011] Summary of the Invention

[0012] The purpose of the present invention is to provide a new class of compounds having α5-GABA Areceptors, in particular, α5-GABA A To this end, the present invention also provides these compounds and pharmaceutically acceptable salts thereof for use in the preparation and manufacture of treating, preventing, or improving α5-GABA A The present invention also provides a method for preparing a compound of formula I and an intermediate useful in such a method.

[0013] In a first aspect of the present invention, there is provided a compound of formula IA, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs:

[0014] in,

[0015] X1 is N or CR5;

[0016] Ring A is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered aromatic ring;

[0017] R1 is selected from halogen, deuterium, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;

[0018] The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0019] p is selected from 0, 1, 2, 3, 4 or 5;

[0020] R2 is selected from hydrogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 heterocycloalkyl;

[0021] The C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0022] m is selected from 0, 1 or 2;

[0023] Alternatively, R2 and R2 together with the carbon atom to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; said 5-8 membered heteroolefin ring is optionally substituted by 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, oxo (=O), hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0024] L1 and L2 are each independently absent or selected from R a Replaced by C 1-6 alkylene;

[0025] Z is selected from NR b , O or S;

[0026] Ring B is selected from a 5-10 membered heteroaromatic ring;

[0027] R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;

[0028] The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo (=O), hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkylsulfone, heterocyclic group, heteroaryl, 1-3 C 1-6 5-10 membered heteroaryl substituted by alkyl, -(C=O)NR7R8, C substituted by 1-3 cyano groups 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9 membered heterocycloalkyl, -SO2-C 1-6 alkyl;

[0029] R4 is selected from halogen, oxo (=O), hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;

[0030] The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0031] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;

[0032] R5 is selected from hydrogen, halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;

[0033] The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0034] R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl, wherein the heteroatoms are selected from one or more of N, S and O, and the number of the heteroatoms is 1, 2 or 3;

[0035] R a Selected from hydrogen, deuterium (D), halogen, oxo (=O), hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0- 6-alkyl-, C 1-6 Alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms;

[0036] R b Selected from hydrogen, deuterium (D), -C 0-6Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 Alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S, the S atom may be in the form of its oxide.

[0037] In a first aspect of the present invention, there is provided a compound of formula I, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs:

[0038] in,

[0039] X1 is N or CR5;

[0040] Ring A is selected from a 5-6 membered heteroaromatic ring or a 6 membered aromatic ring;

[0041] R1 is selected from deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;

[0042] The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0043] p is selected from 0, 1, 2, 3, 4 or 5;

[0044] R2, R6 are each independently selected from hydrogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 heterocycloalkyl;

[0045] The C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7Heterocycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0046] Alternatively, R2 and R6 together with the carbon atom to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; said 5-8 membered heteroolefin ring is optionally substituted by 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0047] L1 and L2 are each independently absent or selected from R a Replaced by C 1-6 alkylene;

[0048] Z is selected from NR b , O or S;

[0049] Ring B is selected from a 5-10 membered heteroaromatic ring;

[0050] When L1 is absent, L2 is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused with a saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl,

[0051] R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;

[0052] The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo (=O), hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkylsulfone, heterocyclic group, heteroaryl, 1-3 C 1-6 5-10 membered heteroaryl substituted by alkyl, -(C=O)NR7R8, C substituted by 1-3 cyano groups 3-6Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9 membered heterocycloalkyl, -SO2-C 1-6 alkyl;

[0053] When L1 is absent, L2 is methylene, X1 is N, R2 is methoxy, the group for When R3 is selected from

[0054] When L1 is absent, Z is O, L2 is methylene, X1 is N, R2 is methoxy, R6 is hydrogen, the group for When R3 is selected from

[0055] When L1 is absent, Z is O, L2 is methylene, X1 is N, R2 is methoxy, R6 is methyl or methoxy, the group for When R3 is selected from

[0056] R4 is selected from deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;

[0057] The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0058] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;

[0059] R5 is selected from hydrogen, halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;

[0060] The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0061] R7 and R8 are independently H or C 1-6Alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl, wherein the heteroatoms are selected from one or more of N, S and O, and the number of the heteroatoms is 1, 2 or 3;

[0062] R a Selected from hydrogen, deuterium (D), halogen, oxo (=O), hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0- 6-alkyl-, C 1-6 Alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms;

[0063] R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 Alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S, the S atom may be in the form of its oxide.

[0064] In a preferred embodiment of the present invention, the compound represented by Formula IA, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, is characterized in that the compound is selected from the following structures:

[0065] in,

[0066] X1 is N or CR5;

[0067] Ring A is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered aromatic ring;

[0068] R1 is selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;

[0069] The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0070] p is selected from 0, 1, 2, 3, 4 or 5;

[0071] R2 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 heterocycloalkyl;

[0072] The R2 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0073] m is selected from 0, 1 or 2;

[0074] L1 and L2 are each independently absent or selected from R a Replaced by C 1-6 alkylene;

[0075] Z is selected from NR b , O or S;

[0076] Ring B is selected from a 5-10 membered heteroaromatic ring;

[0077] R3 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;

[0078] The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo, hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C1- 6 alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkylsulfone, heterocyclic group, heteroaryl, 1-3 C 1-6 5-10 membered heteroaryl substituted by alkyl, -(C=O)NR7R8, C substituted by 1-3 cyano groups 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6- 10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9 membered heterocycloalkyl, -SO2-C 1-6 alkyl;

[0079] R4 is selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;

[0080] The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0081] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;

[0082] R5 is selected from hydrogen, halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;

[0083] The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0084] R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl, wherein the heteroatoms are selected from one or more of N, S and O, and the number of the heteroatoms is 1, 2 or 3;

[0085] R a Selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6Alkyl-, C 1-6 Alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms;

[0086] R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 Alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S, the S atom may be in the form of its oxide.

[0087] In a preferred embodiment of the present invention, the compound represented by Formula I, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, is characterized in that the compound is selected from the following structures:

[0088] in,

[0089] X1 is N or CR5;

[0090] Ring A is selected from a 5-6 membered heteroaromatic ring or a 6 membered aromatic ring;

[0091] R1 is selected from deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;

[0092] The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0093] p is selected from 0, 1, 2, 3, 4 or 5;

[0094] R2 and R6 are each independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 heterocycloalkyl;

[0095] The R2 and R6 are optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0096] L1 and L2 are each independently absent or selected from R a Replaced by C 1-6 alkylene;

[0097] Z is selected from NR b , O or S;

[0098] Ring B is selected from a 5-10 membered heteroaromatic ring;

[0099] When L1 is absent, L2 is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused with a saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl,

[0100] R3 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;

[0101] The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo, hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1- 6 alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkylsulfone, heterocyclic group, heteroaryl, 1-3 C 1-65-10 membered heteroaryl substituted by alkyl, -(C=O)NR7R8, C substituted by 1-3 cyano groups 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6- 10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9 membered heterocycloalkyl, -SO2-C 1-6 alkyl;

[0102] When L1 is absent, L2 is methylene, X1 is N, R2 is methoxy, the group for When R3 is selected from

[0103] R4 is selected from deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl;

[0104] The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0105] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;

[0106] R5 is selected from hydrogen, halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;

[0107] The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0108] R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycloalkyl, wherein the heteroatoms are selected from one or more of N, S and O, and the number of the heteroatoms is 1, 2 or 3;

[0109] R a Selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C0-6 Alkyl-, C 1-6 Alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms;

[0110] R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 Alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S, the S atom may be in the form of its oxide.

[0111] In a preferred embodiment of the present invention, the ring A is selected from a benzene ring or a 5-6 membered heteroaryl group containing 1, 2 or 3 heteroatoms.

[0112] In a preferred embodiment of the present invention, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different;

[0113] In a preferred embodiment of the present invention, ring A is selected from benzene, pyrrole, pyrazole, imidazole, triazole, furan, oxazole, isoxazole, oxadiazole, thiophene, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine or triazine;

[0114] In a preferred embodiment of the present invention, ring A is selected from a benzene ring, isoxazole or oxadiazole.

[0115] In a preferred embodiment of the present invention, ring A is selected from

[0116] In a preferred embodiment of the present invention, R1 is selected from deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl;

[0117] The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different.

[0118] In a preferred embodiment of the present invention, R1 is selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R1 is optionally substituted by 1-4 substituents independently selected from the group consisting of deuterium (D), halogen.

[0119] In a preferred embodiment of the present invention, R1 is selected from deuterium (D), F, Cl, methyl, methoxy, -CHF2, -CF3, -CD3, and cyclopropyl.

[0120] In a preferred embodiment of the present invention, Selected from

[0121] In a preferred embodiment of the present invention, Selected from

[0122] In a preferred embodiment of the present invention, the ring A is selected from a benzene ring or a 5-6 membered heteroaryl group containing 1, 2 or 3 heteroatoms;

[0123] p is 0, 1, 2, 3, 4, or 5;

[0124] R1 is selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-7 Cycloalkyl, C 3-7 Halogenated cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy; when there are multiple substituents, the substituents are the same or different;

[0125] Preferably, the heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different;

[0126] Preferably, ring A is selected from benzene, pyrrole, pyrazole, imidazole, triazole, furan, oxazole, isoxazole, oxadiazole, thiophene, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine or triazine;

[0127] More preferably, ring A is selected from a benzene ring, isoxazole or oxadiazole.

[0128] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0129] Wherein, X2 is N or CR5;

[0130] R5 is selected from hydrogen, deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;

[0131] The R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0132] X1, Ring B, R1, R2, R3, R4, R6, p, n, L1 and L2 are as defined in the first aspect of the present invention.

[0133] In a preferred embodiment of the present invention, R5 is selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R5 is optionally substituted by 1-4 substituents independently selected from the group consisting of deuterium (D), halogen.

[0134] In a preferred embodiment of the present invention, R5 is selected from deuterium (D), F, Cl, methyl, methoxy, -CHF2, -CF3, -CD3, and cyclopropyl.

[0135] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0136] Wherein, X2 is N or CR5;

[0137] R5 is selected from hydrogen, halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;

[0138] The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0139] X1, Ring B, R1, R2, R3, R4, p, m and n are as defined in the first aspect of the present invention;

[0140] The definitions of L1 and L2 are as described in the first aspect of the present invention.

[0141] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0142] Wherein, R5 is selected from hydrogen, deuterium (D), halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl;

[0143] The R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0144] Ring B, R1, R2, R3, R4, R6, n, L1 and L2 are as defined in the first aspect of the present invention.

[0145] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0146] wherein, ring B, R1, R2, R3, R4, m and n are as defined in the first aspect of the present invention;

[0147] The definitions of L1 and L2 are as described in the first aspect of the present invention.

[0148] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0149] Wherein, ring B, R1, R2, R3, R4, L2 and n are as defined in the first aspect of the present invention;

[0150] When L2 is selected from methylene, R2 is selected from methoxy, R1 is selected from methyl, R3 is selected from

[0151] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0152] Wherein, ring B, R1, R2, R3, R4, L2 and n are as defined in the first aspect of the present invention;

[0153] When L2 is selected from methylene, R2 is selected from C 1-6 Alkoxy, R1 is selected from halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy (C 1-6 ) alkyl, C 3-7 Cycloalkyl (C 1-6 ) alkoxy, C 3-7 Cycloalkyl (C 1-6 ) alkoxy (C 1-6 ) alkyl, R3 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 4-10 When it is heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl; said R3 is substituted by 1, 2, 3 or 4 substituents selected from the following: oxo.

[0154] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0155] Wherein, ring B, R1, R2, R3, R4, L2 and n are as defined in the first aspect of the present invention;

[0156] When L2 is selected from methylene, ring B is selected from pyridine, pyridazine, 5-6 membered heteroaromatic ring fused saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl,

[0157] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0158] wherein ring D is a 5-8 membered heterocyclic ring containing at least one O atom;

[0159] Ring B, R1, R2, R3, R4, R6, L1, L2 and n are as defined in the first aspect of the present invention.

[0160] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0161] wherein ring D is a 5-8 membered heterocyclic ring containing at least one O atom;

[0162] Ring B, R1, R2, R3, R4, L1, L2 and n are as defined in the first aspect of the present invention.

[0163] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0164] wherein R2 and R6 are not hydrogen at the same time;

[0165] Ring B, R1, R2, R3, R4, R6, L1, L2 and n are as defined in the first aspect of the present invention.

[0166] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0167] wherein R2 and R6 are hydrogen; Selected from

[0168] R1, R2, R3, R4, R6, L1, L2 and n are as defined in the first aspect of the present invention.

[0169] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0170] Wherein, ring B, R1, R2, R3, R4, R6 and n are defined as described in the first aspect of the present invention.

[0171] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0172] Wherein, ring B, R1, R2, R3, R4, m and n are defined as described in the first aspect of the present invention.

[0173] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0174] Wherein, ring B, R1, R2, R3, R4, R6 and n are defined as described in the first aspect of the present invention.

[0175] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0176] Wherein, ring B, R1, R2, R3, R4, m and n are defined as described in the first aspect of the present invention.

[0177] In a preferred embodiment of the present invention, the ring B is selected from a 5-10 membered heteroaryl group containing 1, 2 or 3 heteroatoms; the heteroatoms are selected from N, O and S; when there are multiple heteroatoms, the heteroatoms are the same or different.

[0178] In a preferred embodiment of the present invention, the ring B is selected from a 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaryl ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7 The heterocycloalkyl group may be saturated or unsaturated, but is not aromatic.

[0179] In a preferred embodiment of the present invention, the ring B is selected from a 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaryl ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7 The heterocycloalkyl group is saturated.

[0180] In a preferred embodiment of the present invention, the ring B is selected from furan, pyridine, pyridazine, pyrimidine, pyrazine, triazine, thiophene, isoxazole, oxazole, oxadiazole, imidazole, pyrrole, pyrazole, triazole, tetrazole, thiazole, isothiazole, thiadiazole, pyridodihydropyridine, pyridomorpholine, pyridopiperidine, and pyridopyrrolidine.

[0181] In a preferred embodiment of the present invention, the ring B is selected from pyridine, pyrimidine, pyridazine, pyridodihydropyridine, and pyridopiperidine.

[0182] In a preferred embodiment of the present invention, the ring B is selected from

[0183] In a preferred embodiment of the present invention, the ring B is selected from a 5-10 membered heteroaryl group containing 1, 2, or 3 heteroatoms;

[0184] The heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different;

[0185] Preferably, ring B is selected from furan, pyridine, pyridazine, pyrimidine, pyrazine, triazine, thiophene, isoxazole, oxazole, oxadiazole, imidazole, pyrrole, pyrazole, triazole, tetrazole, thiazole, isothiazole, thiadiazole, pyridomorpholine, pyridopiperidine, pyridopyrrolidine;

[0186] More preferably, ring B is selected from pyridine, pyrimidine, pyridazine, and pyridopiperidine.

[0187] In a preferred embodiment of the present invention, the ring B is selected from

[0188] In a preferred embodiment of the present invention, Selected from

[0189] In a preferred embodiment of the present invention, Selected from

[0190] In a preferred embodiment of the present invention, L1 is absent, L2 is methylene, and ring B is selected from pyridine, pyridazine, 5-6 membered heteroaromatic ring fused saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl,

[0191] In a preferred embodiment of the present invention, L1 does not exist, L2 is methylene, X1 is N, R2 is methoxy, and the group for When R3 is selected from

[0192] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0193] Wherein, R2 is not tert-butyl,

[0194] R1, R3, R a The definition of is as described in the first aspect of the present invention;

[0195] When R3 is selected from a 4-membered heterocycloalkyl group; the heteroatom is selected from O or S, R1 and R2 are not C 1-6 alkyl;

[0196] When R1 is methyl, R2 is methoxy, R a When all are hydrogen, R3 is selected from

[0197] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0198] Among them, at least one R a Deuterium (D), up to two R a is deuterium (D);

[0199] The definitions of R1, R2 and R3 are the same as those described in the first aspect of the present invention.

[0200] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0201] Wherein, R1, R2, and R3 are as defined in the first aspect of the present invention;

[0202] When R3 is selected from a 4-membered heterocycloalkyl group; the heteroatom is selected from O or S, R1 and R2 are not C1-6 alkyl.

[0203] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0204] Wherein, R2 is not tert-butyl,

[0205] R1 and R3 are as defined in the first aspect of the present invention;

[0206] When R3 is selected from a 4-membered heterocycloalkyl group; the heteroatom is selected from O or S, R1 and R2 are not C 1-6 alkyl;

[0207] When R1 is methyl and R2 is methoxy, R3 is selected from

[0208] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0209] Wherein, R1 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 The cycloalkyl group is substituted with 1 to 4 deuterium (D);

[0210] The definitions of R2 and R3 are the same as those described in the first aspect of the present invention.

[0211] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0212] Wherein, R1, R2, and R3 are as defined in the first aspect of the present invention;

[0213] When R3 is selected from a 4-membered heterocycloalkyl group; the heteroatom is selected from O or S, R1 and R2 are not C 1-6 alkyl.

[0214] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0215] wherein ring D is selected from a 5-6 membered heteroolefin ring; the 5-6 membered heteroolefin ring contains 1 or 2 O;

[0216] The definitions of R1 and R3 are the same as those described in the first aspect of the present invention.

[0217] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0218] Wherein, the definitions of R1 and R3 are as described in the first aspect of the present invention.

[0219] In a preferred embodiment of the present invention, the compound is selected from the following structures:

[0220] Wherein, the definitions of R1 and R3 are as described in the first aspect of the present invention.

[0221] In a preferred embodiment of the present invention, said R1 is selected from deuterium (D), halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 alkoxy;

[0222] The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different.

[0223] In a preferred embodiment of the present invention, the R1 is selected from deuterium (D), F, methyl, -CD3, cyclopropyl, and methoxy.

[0224] In a preferred embodiment of the present invention, p is selected from 0, 1, 2, and 3.

[0225] In a preferred embodiment of the present invention, the p is selected from 1 and 2.

[0226] In a preferred embodiment of the present invention, said R1 is selected from halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 alkoxy;

[0227] The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0228] Preferably, R1 is selected from F, methyl, cyclopropyl, and methoxy.

[0229] In a preferred embodiment of the present invention, R2 is selected from hydrogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 heterocycloalkyl;

[0230] The C 1-3 Alkyl, C1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Heterocycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0231] m is selected from 0, 1 or 2.

[0232] In a preferred embodiment of the present invention, R2 and R6 are each independently selected from hydrogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 heterocycloalkyl;

[0233] The C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Heterocycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different.

[0234] In a preferred embodiment of the present invention, R2 and R6 are each independently selected from H, cyano, methyl, isopropyl, methoxy, cyclopropyl or azetidinyl; and the methyl, isopropyl, methoxy, cyclopropyl or azetidinyl is substituted by 0, 1, 2 or 3 deuterium (D), F, Cl, Br or hydroxyl.

[0235] In a preferred embodiment of the present invention, R2 and R6 are each independently selected from H, cyano, methyl, methoxy, trifluoromethyl, -CHF2, -O-CD3, cyclopropyl,

[0236] In a preferred embodiment of the present invention, R2 and R6 together with the carbon atoms to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring contains 1, 2 or 3 heteroatoms; and the heteroatoms are selected from O, N, S, and P.

[0237] In a preferred embodiment of the present invention, R2 and R6 together with the carbon atoms to which they are attached form a 5-6 membered heteroolefin ring containing at least one O atom.

[0238] In a preferred embodiment of the present invention, said R2 and R6 together with the carbon atom to which they are attached form

[0239] In a preferred embodiment of the present invention, R2 and R2 together with the carbon atom to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring contains 1, 2 or 3 heteroatoms; and the heteroatoms are selected from O, N, S, and P.

[0240] In a preferred embodiment of the present invention, R2 and R3 together with the carbon atom to which they are attached form a 5-6 membered heteroolefin ring containing at least one O atom.

[0241] In a preferred embodiment of the present invention, said R2 and R2 together with the carbon atom to which they are attached form

[0242] In a preferred embodiment of the present invention, R2 is selected from H, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 heterocycloalkyl;

[0243] The R2 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0244] m is selected from 0, 1 or 2;

[0245] Preferably, R2 is selected from H, methyl, isopropyl, methoxy, cyclopropyl or azetidinyl;

[0246] The R2 is substituted by 0, 1 or 2 F, Cl, Br or hydroxyl groups.

[0247] In a preferred embodiment of the present invention, R2 is selected from H, CN, methyl, methoxy, cyclopropyl, trideuteromethoxy, difluoromethyl, trifluoromethyl,

[0248] In a preferred embodiment of the present invention, X1 is selected from N or CH.

[0249] In a preferred embodiment of the present invention, the ring D is selected from a 5-8 membered heterocyclic ring containing at least one O atom; the 5-8 membered heterocyclic ring is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different.

[0250] In a preferred embodiment of the present invention, the ring D is selected from a 5-8 membered heterocycloalkyl group containing at least one O atom.

[0251] In a preferred embodiment of the present invention, the ring D is selected from dioxane or

[0252] In a preferred embodiment of the present invention, said L1 is absent or selected from R a Replaced by C 1-3 Alkylene.

[0253] In a preferred embodiment of the present invention, L1 is absent or selected from methylene, carbonyl, -CHD-, -CD2-, and -CH(CH3)-.

[0254] In a preferred embodiment of the present invention, L1 is absent or selected from methylene, carbonyl, and -CH(CH3)-.

[0255] In a preferred embodiment of the present invention, said L1 is absent or selected from R a Replaced by C 1-3 alkylene;

[0256] Preferably, the L1 is absent or selected from alkylene, -CH(CH3)-.

[0257] In a preferred embodiment of the present invention, said L2 is absent or selected from R a Replaced by C 1-3 Alkylene.

[0258] In a preferred embodiment of the present invention, L2 is absent or selected from methylene, carbonyl, -CHD-, -CD2-, -CH(CH3)-.

[0259] In a preferred embodiment of the present invention, L2 is absent or selected from methylene, carbonyl, -CH(CH3)-.

[0260] In a preferred embodiment of the present invention, said L2 is absent or selected from R a Replaced by C 1-3 alkylene;

[0261] Preferably, the L2 is absent or selected from alkylene, -CH(CH3)-.

[0262] In a preferred embodiment of the present invention, Z is selected from NR b , O or S; said R b Selected from hydrogen, deuterium (D), -C0-3 Alkyl-S(=O)2-C 0-3 Alkyl-, -C 0-3 Alkyl-P(=O)2-C 0-3 Alkyl-, C 1-3 Alkyl or 3-4 membered heterocycloalkyl.

[0263] In a preferred embodiment of the present invention, Z is selected from NH or O.

[0264] In a preferred embodiment of the present invention, Selected from (like ),

[0265] In a preferred embodiment of the present invention, R3 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl;

[0266] In a preferred embodiment of the present invention, said R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 4-6 Heterocycloalkyl; said R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo, hydroxyl, C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkoxy.

[0267] In a preferred embodiment of the present invention, said R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy; said R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo, hydroxyl, C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkoxy.

[0268] In a preferred embodiment of the present invention, said R3 is selected from C 4-6 Heterocycloalkyl; said R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo. In a preferred embodiment of the present invention, said R3 is selected from cyano, C 1-6 Alkyl, C substituted by hydroxy 1-6 Alkyl, C 1- 6-alkyl-C 1-3 Alkoxy-C 1-6 Alkoxy, C4-6 Heterocycloalkyl, C substituted by halogen 4-6 Heterocycloalkyl, C substituted by oxo (=O) 4-6 Heterocycloalkyl.

[0269] In a preferred embodiment of the present invention, R3 is selected from cyano, methyl, ethyl, propyl, isopropyl, oxetanyl, tetrahydropyran, piperazine,

[0270] In a preferred embodiment of the present invention, said R3 is selected from cyano, ethyl,

[0271] In a preferred embodiment of the present invention, said R3 is selected from C 4-6 heterocycloalkyl;

[0272] The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo; when there are multiple substituents, the substituents are the same or different;

[0273] Preferably, R3 is selected from oxetane, piperazine,

[0274] More preferably, R3 is selected from

[0275] In a preferred embodiment of the present invention, said R3 is selected from cyano, ethyl, (like ),

[0276] In a preferred embodiment of the present invention, R4 is selected from deuterium (D), halogen, oxo (=O), hydroxyl, CN, C 1-3 Alkyl, C 3-5 Cycloalkyl; said R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7.

[0277] In a preferred embodiment of the present invention, R4 is selected from deuterium (D) and oxo (═O); and n is selected from 0 or 1.

[0278] In a preferred embodiment of the present invention, said R4 is selected from halogen, hydroxyl, C 1-3 Alkyl, C 3-5 Cycloalkyl;

[0279] The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different;

[0280] n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;

[0281] Preferably, n is selected from 0.

[0282] In a preferred embodiment of the present invention, the compound comprises:

[0283] In a preferred embodiment of the present invention, the compound comprises:

[0284] The second aspect of the present invention is a pharmaceutical composition comprising the compound of formula I as described in the first aspect, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs; and a pharmaceutically acceptable carrier.

[0285] The third aspect of the present invention is the use of the compound of formula I as described in the first aspect, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the use of the pharmaceutical composition as described in the second aspect, wherein the use includes:

[0286] Regulation of α5-GABA A receptors;

[0287] and / or, prevention and / or treatment of α5-GABA A Receptor-related diseases;

[0288] and / or, preparing a method for regulating α5-GABA A Receptors, and / or prevention and / or treatment of α5-GABA A A drug, pharmaceutical composition or preparation for a disease associated with a receptor.

[0289] Provided are compounds of formula I as described in the first aspect, their tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the pharmaceutical composition described in the second aspect, which are expected to be used for pain, Alzheimer's disease, multi-infarct dementia or stroke.

[0290] Pain that should be mentioned is neuropathic pain, inflammatory pain or cancer pain.

[0291] The pain that should be mentioned is selected from the group consisting of headache, facial pain, neck pain, shoulder pain, back pain, chest pain, abdominal pain, low back pain, lower limb pain, muscle and bone pain, vascular pain, gout, arthritis pain, visceral pain, pain caused by infectious diseases, polyostotic pain, sickle cell anemia, autoimmune diseases, pain associated with multiple sclerosis or inflammation, chronic pain caused by injury or surgery, nociceptive pain, painful diabetes, trigeminal neuralgia, lumbar or cervical radiculopathy, glossopharyngeal neuralgia, autonomic reflex pain, reflex sympathetic dystrophy, nerve root avulsion, cancer, chemical injury, toxins, nutritional deficiencies, viral or bacterial infections, and pain associated with degenerative osteoarthritis.

[0292] Infectious diseases that should be mentioned are selected from AIDS or postherpetic neuralgia.

[0293] In a fourth aspect, the present invention provides a method for regulating α5-GABA. A A method for treating a receptor-related disease, comprising administering to a patient a preventive or therapeutically effective amount of a compound of Formula I, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the pharmaceutical composition of the second aspect.

[0294] In some embodiments, a method for preventing and / or treating α5-GABA is provided. A A method for treating a receptor-related disease, comprising administering to a patient a preventive or therapeutically effective amount of a compound of formula I, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the pharmaceutical composition of the second aspect.

[0295] The disease is selected from pain, Alzheimer's disease, multi-infarct dementia or stroke.

[0296] Pain that should be mentioned is selected from neuropathic pain, inflammatory pain or cancer pain.

[0297] The pain that should be mentioned is selected from the group consisting of headache, facial pain, neck pain, shoulder pain, back pain, chest pain, abdominal pain, low back pain, lower limb pain, muscle and bone pain, vascular pain, gout, arthritis pain, visceral pain, pain caused by infectious diseases, polyostotic pain, sickle cell anemia, autoimmune diseases, pain associated with multiple sclerosis or inflammation, chronic pain caused by injury or surgery, nociceptive pain, painful diabetes, trigeminal neuralgia, lumbar or cervical radiculopathy, glossopharyngeal neuralgia, autonomic reflex pain, reflex sympathetic dystrophy, nerve root avulsion, cancer, chemical injury, toxins, nutritional deficiencies, viral or bacterial infections, and pain associated with degenerative osteoarthritis.

[0298] Infectious diseases that should be mentioned are selected from AIDS or postherpetic neuralgia.

[0299] In a fifth aspect of the present invention, the compound represented by formula I as described in the first aspect, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the pharmaceutical composition as described in the second aspect is used as a drug.

[0300] In a sixth aspect of the present invention, the compound of formula I according to the first aspect, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the pharmaceutical composition according to the second aspect is used for:

[0301] Regulation of α5-GABA A receptors;

[0302] For the prevention and / or treatment of α5-GABA A Receptor-related diseases.

[0303] The disease is selected from pain, Alzheimer's disease, multi-infarct dementia or stroke.

[0304] Pain that should be mentioned is selected from neuropathic pain, inflammatory pain or cancer pain.

[0305] The pain that should be mentioned is selected from the group consisting of headache, facial pain, neck pain, shoulder pain, back pain, chest pain, abdominal pain, low back pain, lower limb pain, muscle and bone pain, vascular pain, gout, arthritis pain, visceral pain, pain caused by infectious diseases, polyostotic pain, sickle cell anemia, autoimmune diseases, pain associated with multiple sclerosis or inflammation, chronic pain caused by injury or surgery, nociceptive pain, painful diabetes, trigeminal neuralgia, lumbar or cervical radiculopathy, glossopharyngeal neuralgia, autonomic reflex pain, reflex sympathetic dystrophy, nerve root avulsion, cancer, chemical injury, toxins, nutritional deficiencies, viral or bacterial infections, and pain associated with degenerative osteoarthritis.

[0306] Infectious diseases that should be mentioned are selected from AIDS or postherpetic neuralgia.

[0307] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. Beneficial effects

[0308] The present inventors have unexpectedly developed a compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof after extensive and in-depth research.

[0309] The present invention provides a compound of formula I, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, wherein the compound of formula I has an effect on α5-GABA. AThe receptor has a significant regulatory effect and can treat α5-GABA A Receptor-mediated diseases or conditions, showing excellent pharmacokinetic properties, and possessing high safety and drugability.

[0310] The present invention provides a method for preparing the compound shown in I, its tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, and intermediates. The method is simple to operate, has high yield and high purity, and can be used for industrial production of pharmaceuticals. BRIEF DESCRIPTION OF THE DRAWINGS

[0311] Figure 1. Thermal pain threshold of rats in the rat CFA inflammatory pain model after testing compounds.

[0312] Definitions and Explanations of Terms

[0313] Unless otherwise indicated, the definitions of groups and terms in this specification and claims, including definitions used as examples, exemplary definitions, preferred definitions, definitions in tables, and definitions of specific compounds in the Examples, may be arbitrarily combined and coupled with one another. The resulting group definitions and compound structures shall fall within the scope of the description of this specification.

[0314] Unless otherwise defined, all technical and scientific terms herein have the same meanings as commonly understood by persons skilled in the art to which the claimed subject matter belongs. Unless otherwise indicated, all patents, patent applications, and publications cited herein are incorporated by reference in their entirety. If multiple definitions of a term are used herein, the definitions in this section shall prevail.

[0315] It should be understood that the above brief description and the detailed description below are exemplary and are only used for explanation, and do not impose any restrictions on the subject matter of the present invention. In this application, unless otherwise specifically stated, the use of the singular also includes the plural. It must be noted that unless otherwise clearly stated in the text, the singular forms used in this specification and claims include the plural forms of the things referred to. It should also be noted that unless otherwise stated, the use of "or" and "or" means "and / or". In addition, the use of the term "including" and other forms, such as "comprising", "including" and "containing" are not restrictive.

[0316] Definitions of standard chemical terms can be found in the references (including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4THED." Vols. A (2000) and B (2001), Plenum Press, New York). Unless otherwise indicated, conventional methods within the skill of the art, such as mass spectrometry, NMR, IR and UV / VIS spectroscopy and pharmacological methods, are used. Unless otherwise specified, the terms used herein in the descriptions of analytical chemistry, synthetic organic chemistry, and pharmaceuticals and medicinal chemistry are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and in the treatment of patients. For example, the manufacturer's instructions for use of the kit can be utilized, or reactions and purifications can be carried out in accordance with methods well known in the art or the description of the present invention. The above techniques and methods can generally be implemented according to conventional methods well known in the art, as described in the various general and more specific references cited and discussed in this specification. In this specification, groups and substituents thereof can be selected by those skilled in the art to provide stable structural moieties and compounds.

[0317] When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes chemically equivalent substituents that would result from writing the formula from right to left. For example, CHO is equivalent to OCH. As used herein, As used herein, "R1", "R2" and "R 1 " have the same meaning and can be replaced with each other. For other symbols such as R2, similar definitions have the same meaning.

[0318] The section headings used herein are for organizational purposes only and should not be construed as limitations on the subject matter described. All documents or portions of documents cited in this application, including but not limited to patents, patent applications, articles, books, manuals, and papers, are incorporated herein by reference in their entirety.

[0319] In addition to the foregoing, when used in the specification and claims of this application, the following terms have the meanings indicated below unless otherwise specifically stated.

[0320] When a numerical range is described in the specification and claims of this application and is understood as an "integer," it should be understood to include both endpoints of the range as well as every integer within the range. For example, "an integer from 1 to 6" should be understood to include every integer from 0, 1, 2, 3, 4, 5, and 6.

[0321] In this application, when specifying the number of substituents, the term "one or more" refers to one substitution to the maximum possible number of substitutions, i.e., replacing one hydrogen to replacing all hydrogens with substituents. When specifying the number of substituents, the term "1-4" refers to 1, 2, 3, or 4 substitutions, i.e., replacing 1, 2, 3, or 4 hydrogens with substituents.

[0322] In the present application, "saturated, partially saturated or unsaturated" includes substituents saturated with hydrogen, substituents completely unsaturated with hydrogen and substituents partially saturated with hydrogen.

[0323] As used herein, the term "halogen" by itself or as part of another substituent refers to fluorine, chlorine, bromine, or iodine.

[0324] As used herein, the term "hydroxy" by itself or as part of another substituent refers to -OH.

[0325] As used herein, the term "cyano" by itself or as part of another substituent refers to -CN.

[0326] As used herein, the term "amino" by itself or as part of another substituent refers to -NH2.

[0327] In this application, the term "alkyl" when used alone or as part of another substituent means a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, having, for example, 1 to 6 carbon atoms and connected to the rest of the molecule by a single bond. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl and hexyl. Alkyl groups can be unsubstituted or substituted with one or more suitable substituents. Alkyl groups can also be isotopomers of naturally abundant alkyl groups that are rich in isotopes of carbon and / or hydrogen (i.e., deuterium or tritium).

[0328] In this application, the term "C α-β "Alkyl" refers to an alkyl group containing a minimum of α and a maximum of β carbon atoms in a branched or linear relationship or any combination of the three, where α and β represent integers and can also be represented by "C α- C β The alkyl groups described in this section may also contain one or two double bonds or triple bonds. The designation of C0 alkyl indicates a direct bond. 1-6 Examples of alkyl groups include, but are not limited to, the following:

[0329] In this application, "benzo group" alone or in combination refers to a divalent group C4H4=, one of which is represented by -CH=CH-CH=CH-, which forms a benzene-like ring when attached to another ring in the ortho position, such as tetralin, indole, etc.

[0330] In this application, the term "C α-β "Haloalkyl" refers to an alkyl group as described above wherein any number (at least one) of the hydrogen atoms attached to the alkyl chain are replaced by fluorine, chlorine, bromine or iodine.

[0331] As used herein, the term "alkoxy" refers to the group -OR Q , where R Q is an "alkyl" group as defined above.

[0332] In this application, the term "oxo" when used alone or as part of other substituents refers to the replacement of two hydrogen atoms on a methylene group by oxygen atoms, ie, the methylene group is replaced by a carbonyl group, representing =0.

[0333] As used herein, the term "thio" by itself or as part of another substituent refers to the replacement of two hydrogen atoms on a methylene group by sulfur, representing =S.

[0334] In this application, the term "cycloalkyl" or "carbocyclyl" when used alone or as part of another substituent refers to a cyclic alkyl group. m -C n Cycloalkyl" or "C m-n "Cycloalkyl" is understood to mean a saturated, unsaturated or partially saturated carbon ring having m to n atoms, but which is not aromatic. For example, "3-15 membered cycloalkyl" or "C3-C 15 "Cycloalkyl" refers to a cyclic alkyl group containing 3 to 15, 3 to 9, 3 to 6 or 3 to 5 carbon atoms, which may contain 1 to 4 rings. "5-8 membered cycloalkyl" contains 5-8 carbon atoms. It includes monocyclic, bicyclic, tricyclic, spirocyclic or bridged rings. Examples of unsubstituted cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and adamantyl, or a bicyclic hydrocarbon group such as a decalin ring. The cycloalkyl group may be substituted with one or more substituents. In some embodiments, the cycloalkyl group may be a cycloalkyl group fused to an aryl or heteroaryl group. The term "C3-C6 cycloalkyl" should be understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3 to 6 carbon atoms, including fused or bridged polycyclic ring systems. For example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.

[0335] In this application, the term "heterocycloalkyl" or "heterocyclyl" when alone or as part of other substituents refers to a cycloalkyl group in which one or more (in some embodiments 1 to 3, such as 1, 2 or 3) carbon atoms are replaced by heteroatoms, such as but not limited to N, O, S and P. "Heterocycloalkyl" or "heterocyclyl" can be saturated or unsaturated, but not aromatic. "Heterocycloalkyl" or "heterocyclyl" can also contain 1, 2 or 3 rings, including bridged rings and spirocyclic structures. The term "3-10 membered heterocyclyl" or "3-10 membered heterocycloalkyl" should be understood to mean a monocyclic, bicyclic or tricyclic ring having 3 to 10 atoms (e.g., 3, 4, 5, 6, 7, 8, 9, 10), wherein the heteroatoms are preferably selected from N, O and S. It should be understood that when the total number of S atoms and O atoms in the heterocyclyl exceeds 1, these heteroatoms are not adjacent to each other. The term "C 4-10 "Heterocycloalkyl" is understood to mean a monocyclic, bicyclic or tricyclic ring having 4 to 10 atoms (e.g. 4, 5, 6, 7, 8, 9, 10), having 1 to 3 heteroatoms, preferably selected from N, O and S, exemplarily selected from 3-6 membered heterocycloalkyl, 4-6 membered heterocycloalkyl, 3-7 membered heterocycloalkyl, 3-9 membered heterocycloalkyl, 4-10 membered heterocycloalkyl. Examples of the term heterocycloalkyl include, but are not limited to, oxetanyl, azetidinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothiopyranyl.

[0336] In this application, the term "C α-β "Cycloalkenyl" refers to a monocyclic group having α to β atoms, a double bond, but no aromaticity. Examples of cycloalkenyl groups include cyclopropene, cyclobutene, cyclohexene, cyclobutadiene, cyclopentadiene, cycloheptatriene, and cyclooctatetraene.

[0337] In this application, the term "heteroalkene ring" when used alone or as part of another substituent refers to a monocyclic group having a heteroatom (the monocyclic group has a double bond but is not aromatic), preferably a monocyclic ring containing 1, 2 or 3 ring heteroatoms independently selected from N, O and S. Examples of heterocycloalkenyl groups are: dihydrofuranyl, dihydrothiophenyl, dihydropyrrolyl, dioxolyl, dihydroimidazolyl, dihydropyrazolyl, dihydrothiazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrothiadiazolyl, dihydrotriazolyl, dihydrotetrazolyl, tetrahydropyridinyl, 3,4-dihydro-2H-pyran, pyranyl, thiopyranyl, dihydropyridinyl, dihydropyrazinyl, dihydropyrimidinyl, oxazinyl, dihydrotetrazolyl, and the like. The term "heteroalkene ring" can be used interchangeably with the term "heterocycloalkenyl".

[0338] As used herein, the term "aryl" or "aromatic ring," when used alone or as part of another substituent, refers to a monovalent aromatic carbocyclic ring system containing 6 to 14, preferably 6 to 10, carbon atoms and having at least one aromatic ring or multiple fused rings in which at least one ring is aromatic. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, biphenyl, indanyl, and the like.

[0339] As used herein, the term "5-14 membered heteroaromatic ring" or "5-14 membered heteroaryl" when used alone or as part of another substituent group refers to a stable monocyclic, bicyclic or tricyclic ring having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, wherein at least one ring is aromatic and at least one ring contains 1 to 5 heteroatoms independently selected from N, O and S. It should be understood that when the total number of S atoms and O atoms in the heteroaryl exceeds 1, these heteroatoms are not adjacent to each other. The 5-14 membered heteroaryl can be attached to the rest of the molecule through a heteroatom or a carbon atom. 5-14 membered heteroaryl groups within the scope of this definition include, but are not limited to, acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, quinazolinyl, pyrazolyl, indolyl, isoindolyl, 1H,3H-1-oxoisoindolyl, benzotriazolyl, furanyl, thienyl, pyridomorpholinyl, pyridopiperidinyl, pyridopyrrolidinyl, benzothienyl, benzofuranyl, benzodioxane, benzodioxabenzyl, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, benzotriazolyl, benzothiophene, benzofuranyl, benzodioxane, benzodioxabenzyl, benzothiophene, benzofuranyl, benzodioxane, benzodioxabenzyl, benzothiophene, benzofuranyl, benzodioxane, benzodioxabenzyl, benzothiophene, benzothiophene, benzofuranyl, benzodioxane, benzodioxabenzyl, benzothiophene, benzothiophene, benzofuranyl, benzodioxane, benzodioxabenzyl, benzothiophene, benzothiophene, benzothiophene, benzofuranyl, benzodioxane, benzodioxabenzyl, benzofuran ... The term "5-10 membered heteroaromatic ring" or "5-10 membered heteroaryl" is understood to mean a monocyclic, bicyclic or tricyclic ring having 5 to 10 atoms, wherein at least one ring is aromatic and contains at least 1 to 5 heteroatoms independently selected from N, O and S. In the present application, the term "5-10 membered heteroaromatic ring" or "5-10 membered heteroaryl" shall include 5-10 membered heteroaromatic ring monocyclic ring, fused bicyclic ring having 5 to 10 atoms, said 5 to 10 membered heteroaromatic ring fused bicyclic ring including 5 membered heteroaromatic ring and C 5-7 Heteroaromatic ring, 6-membered heteroaromatic ring and C 5-6 Heteroaromatic ring, 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaryl ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7Heterocycloalkyl may be saturated or unsaturated, but is not aromatic. Examples of 5-10 membered heteroaromatic rings include, but are not limited to, furyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridomorpholinyl, pyridopiperidinyl, pyridopyrrolidinyl, and the like.

[0340] In this application, the term "monocyclic" when used alone or as part of another substituent means a group having only one ring, which may be saturated, unsaturated or partially saturated, and may be carbocyclic (all ring atoms are carbon atoms) or heterocyclic (in addition to carbon atoms, the ring atoms include, for example, 1, 2 or 3 heteroatoms, such as N, O or S).

[0341] In this application, the term "bicyclic" means a group having two connected rings when used alone or as part of other substituents. Bicyclic can be a carbocyclic ring (all ring atoms are carbon atoms) or a heterocyclic ring (in addition to carbon atoms, the ring atoms include, for example, 1, 2 or 3 heteroatoms, such as N, O or S). Both rings can be aliphatic (e.g., decalin and norbornane), or can be aromatic (e.g., naphthalene), or a combination of aliphatic and aromatic (e.g., tetralin). Bicyclic includes (a) spirocyclic compounds, in which the two rings share only one single atom (spiro atom, which is typically a quaternary carbon). Examples of spirocyclic compounds include, but are not limited to:

[0342] It also includes spirocycloalkyl groups that share a spiro atom with a heterocycloalkyl group. Non-limiting examples include:

[0343] (b) Fused bicyclic compounds, where the two rings share two adjacent atoms. In other words, the rings share a covalent bond, i.e., the bridgehead atoms are directly connected (e.g., α-thujene and decalin). Examples of fused bicyclic rings include, but are not limited to:

[0344] and (c) bridged bicyclic compounds in which the two rings share three or more atoms and the two bridgehead atoms are separated by a bridge comprising at least one atom. For example, norbornane, also known as bicyclo[2.2.1]heptane, can be considered a pair of cyclopentane rings, each sharing three of their five carbon atoms. Examples of bridged bicyclic rings include, but are not limited to:

[0345] In this application, the term "inert solvent" includes, but is not limited to, toluene, benzene, water, methanol, ethanol, isopropanol, ethylene glycol, N-methylpyrrolidone, dimethyl sulfoxide, tetrahydrofuran, dichloromethane, chloroform, 1,2-dichloroethane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, or a combination thereof.

[0346] Compounds provided herein include intermediates that can be used to prepare compounds provided herein, which contain reactive functional groups (such as, but not limited to, carboxyl, hydroxyl, and amino moieties), and also include protected derivatives thereof."Protected derivatives" are compounds in which one or more reactive sites are blocked by one or more protecting groups (also referred to as blocking groups). Suitable carboxyl moiety protecting groups include benzyl, tert-butyl, etc., and isotopes, etc. Suitable amino and amido protecting groups include acetyl, trifluoroacetyl, tert-butyloxycarbonyl, benzyloxycarbonyl, etc. Suitable hydroxyl protecting groups include benzyl, etc. Other suitable blocking groups are well known to those of ordinary skill in the art.

[0347] In this application, the term "optionally substituted by" or "optionally substituted by" means that the specified group is unsubstituted or substituted by one or more substituents independently selected from the possible substituents. For example, "aryl is optionally substituted by 1-4 substituents independently selected from the following groups: halogen, cyano, hydroxy, C 1-6 "Alkyl" means that the aryl group is unsubstituted or substituted by 1, 2, 3 or 4 substituents independently selected from the following groups: halogen, cyano, hydroxy, C 1-6 The term "alkyl" refers to an alkyl group, and the description includes both substituted and unsubstituted aryl groups.

[0348] In this application, the term "salt" or "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0349] As used herein, the term "pharmaceutically acceptable acid addition salt" refers to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. A "pharmaceutically acceptable base addition salt" refers to salts formed with inorganic or organic bases that retain the biological effectiveness of the free acid without other side effects. In addition to pharmaceutically acceptable salts, other salts are contemplated herein. These salts may serve as intermediates in the purification of compounds or in the preparation of other pharmaceutically acceptable salts, or may be used in the identification, characterization, or purification of the compounds of the invention.

[0350] In the present application, the term "amine salt" refers to a product obtained by neutralizing an alkyl primary amine, secondary amine or tertiary amine with an acid, including an inorganic acid or an organic acid as described in the present application.

[0351] In the present application, the term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers and conformational isomers.

[0352] Depending on the choice of starting materials and methods, the compounds of the present invention may exist in one of the possible isomers or in a mixture thereof, for example as pure optical isomers, or as a mixture of isomers, such as a racemic and diastereomeric mixture, depending on the number of asymmetric carbon atoms. When describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule with respect to the chiral center (or centers) in the molecule. The prefixes D and L or (+) and (–) are used to designate the signs for the rotation of plane-polarized light caused by the compound, where (–) or L indicates that the compound is levorotatory. Compounds prefixed with (+) or D are dextrorotatory.

[0353] When bonds to chiral carbon atoms in the present formulae are depicted as straight lines, it is understood that both the (R) and (S) configurations of the chiral carbon atoms and the enantiomerically pure compounds and mixtures thereof are encompassed within the scope of the formula. The diagrammatic representation of racemates or enantiomerically pure compounds herein is adapted from Maehr, J. Chem. Ed. 1985, 62:114-120. Wedge-shaped bonds and dashed bonds are used to represent the absolute configuration of a stereocenter.

[0354] As used herein, the term "tautomer" refers to functional group isomers resulting from the rapid shift of an atom between two positions in a molecule. Compounds of the present invention may exhibit tautomerism. Tautomeric compounds may exist as two or more interconvertible species. Prototropic tautomers result from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium, and attempts to isolate a single tautomer typically produce a mixture whose physical and chemical properties are consistent with a mixture of compounds. The position of equilibrium depends on the chemical properties within the molecule. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form predominates, while in phenols, the enol form predominates. The present invention encompasses all tautomeric forms of the compounds.

[0355] As used herein, the term "pharmaceutical composition" refers to a formulation of a compound of the present invention and a medium generally accepted in the art for delivering a biologically active compound to a mammal (e.g., a human). The medium includes a pharmaceutically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration to an organism, thereby facilitating absorption of the active ingredient and thereby exerting its biological activity.

[0356] In this application, the term "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant governmental regulatory authorities as acceptable for human or veterinary use.

[0357] In the present application, the term "solvate" refers to a compound of the present invention or a salt thereof including a stoichiometric or non-stoichiometric amount of a solvent bound by intermolecular non-covalent forces. When the solvent is water, it is a hydrate.

[0358] As used herein, the term "prodrug" refers to a compound of the present invention that can be converted to a biologically active compound under physiological conditions or by solvolysis. Prodrugs of the present invention are prepared by modifying functional groups within the compound. These modifications can be removed by conventional procedures or in vivo to yield the parent compound. Prodrugs include compounds in which a hydroxyl or amino group within a compound of the present invention is attached to any group. When a prodrug of a compound of the present invention is administered to a mammalian subject, the prodrug is cleaved to form a free hydroxyl group or free amino group, respectively.

[0359] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms constituting the compound, said isotopes having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. For example, the compounds may be labeled with radioactive isotopes, such as deuterium ( 2 H or D), tritium ( 3 H or T), iodine-125 ( 125 I) or C-14( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of this invention. Isotopic variations may offer certain therapeutic advantages, for example, deuterium enrichment may increase in vivo half-life or reduce dosage requirements, or may provide a standard compound useful for characterizing biological samples. Isotopically enriched compounds within Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art, or by methods analogous to those described in the schemes and examples herein, using appropriate isotopically enriched reagents and / or intermediates.

[0360] As used herein, the term "excipient" refers to a pharmaceutically acceptable inert ingredient. Examples of the term "excipient" include, but are not limited to, binders, disintegrants, lubricants, glidants, stabilizers, fillers, and diluents. Excipients enhance the handling characteristics of pharmaceutical formulations, i.e., by increasing flowability and / or adhesion, making the formulation more suitable for direct compression.

[0361] As used herein, the term "treat" and other similar synonyms include the following meanings:

[0362] (i) preventing a disease or condition from occurring in a mammal, particularly where such mammal is susceptible to the disease or condition but has not yet been diagnosed as having the disease or condition;

[0363] (ii) inhibiting the disease or condition, i.e., curbing its development;

[0364] (iii) alleviate the disease or condition, that is, cause regression of the disease or condition; or

[0365] (iv) Alleviate the symptoms of the disease or condition.

[0366] The reaction temperature and reaction time for each step can be appropriately selected based on the solvent, starting materials, reagents, and other factors. After the completion of each step, the target compound can be isolated and purified from the reaction system using conventional methods, such as filtration, extraction, recrystallization, washing, and silica gel column chromatography. The target compound can also be directly used in the next step without isolation or purification, provided this does not affect the next step. DETAILED DESCRIPTION

[0367] The present invention will be further described below in conjunction with specific examples. It should be understood that the following description is only the most preferred embodiment of the present invention and should not be considered as limiting the scope of protection of the present invention. Based on a full understanding of the present invention, the experimental methods in the following examples that do not specify specific conditions are generally carried out under conventional conditions or under conditions recommended by the manufacturer. Those skilled in the art may make non-essential changes to the technical solutions of the present invention, and such changes should be considered as included in the scope of protection of the present invention.

[0368] This application has the following definitions:

[0369] Symbol or unit:

[0370] IC 50 : Half-maximal inhibitory concentration, which refers to the concentration at which half of the maximum inhibitory effect is achieved

[0371] M: mol / L, for example, n-butyllithium (14.56 mL, 29.1 mmol, 2.5 M n-hexane solution) means a n-butyllithium n-hexane solution with a molar concentration of 2.5 mol / L

[0372] N: equivalent concentration, for example, 2N hydrochloric acid means 2 mol / L hydrochloric acid solution

[0373] RT: retention time

[0374] Reagents:

[0375] PE: Petroleum ether

[0376] EA: also written as EtOAc, ethyl acetate

[0377] DCM: dichloromethane

[0378] MeOH: methanol

[0379] DMF: N,N-dimethylformamide

[0380] DIPEA: N,N-diisopropylethylamine

[0381] Pd2(dba)3: tris(dibenzylideneacetone)dipalladium

[0382] Pd(dppf)Cl2:(1,1'-bis(diphenylphosphino)ferrocene)palladium dichloride

[0383] Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

[0384] HATU: 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate

[0385] Test method:

[0386] LCMS: Liquid chromatography-mass spectrometry

[0387] TLC: Thin layer chromatography

[0388] Intermediates A1 and A2: Preparation of 6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile and 6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile

[0389] 6-Chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile (Intermediate A1)

[0390] 6-Chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile (Intermediate A2)

[0391] The synthetic routes of intermediates A1 and A2 are as follows:

[0392] Step 1: Synthesis of 6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile and 6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile

[0393] 3,6-Dichloropyridazine-4-carbonitrile (5.0 g, 28.7 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (4.0 g, 28.7 mmol) were added sequentially to 25 mL of n-butanol and heated under reflux for 4 hours under nitrogen protection. The reaction system was cooled to room temperature and concentrated. The crude product was purified by silica gel column chromatography (PE / EA (V / V) = 3 / 1) to give 6-chloro-3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile (320 mg) and 6-chloro-3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile (3.4 g, yield: 49.6%).

[0394] LC-MS, M / Z(ESI+):261.0[M+H] +

[0395] Intermediate A3: Preparation of (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol

[0396] The preparation method of intermediate A3 refers to patent WO2021121294A1.

[0397] Example 1: Preparation of target compound I-5

[0398] 3-(7-cyclopropyl-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0399] The synthetic route of target compound I-5 is as follows:

[0400] Step 1: Synthesis of 3,6-dichloro-4-cyclopropylpyridazine

[0401] To a suspension of 3,6-dichloropyridazine (10.00 g, 67.12 mmol) in water (300 mL) was added 10 mL of concentrated sulfuric acid and cyclopropanecarboxylic acid (5.85 mL, 73.7 mmol), heated at 70° C. and degassed with N 2. A solution of silver nitrate (2.28 g, 13.4 mmol) in 10 mL of water was added over 30 seconds, followed by the dropwise addition of a solution of ammonium persulfate (46 g, 201.577 mmol) in 150 mL of water over 30 minutes. The reaction was allowed to proceed for 1 hour. LCMS showed that the reaction was complete. The mixture was cooled to room temperature and poured onto ice. Ammonia was added dropwise to adjust the pH of the solution to 9. The mixture was extracted three times with ethyl acetate (100 mL). The organic phases were combined and washed with saturated brine (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (PE / EA (V / V) = 2 / 3) to give 3,6-dichloro-4-cyclopropylpyridazine (6.83 g, yield: 54%).

[0402] Step 2: 3-(6-chloro-7-cyclopropyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0403] 3,6-Dichloro-4-cyclopropylpyridazine (5.33 g, 28.3 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (4.0 g, 28.3 mmol) were added sequentially to 30 mL of n-butanol. The mixture was heated under reflux under argon for 4 hours. The solvent was evaporated to dryness, and the solid was slurried with 40 mL of dichloromethane for 2 hours. The insoluble matter was filtered, and the organic phase was concentrated. The residue was purified by silica gel chromatography (PE / EA (V / V) = 1 / 1) to provide 3-(6-chloro-7-cyclopropyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (600 mg, yield: 7.7%).

[0404] Step 3: 3-(7-cyclopropyl-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0405] At room temperature, 3-(6-chloro-7-cyclopropyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.54 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (120 mg, 0.54 mmol) and cesium carbonate (354 mg, 1.14 mmol) were dissolved in acetonitrile (6 mL). The reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, which was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, followed by extraction with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The organic phase was filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by preparative reverse-phase high performance liquid chromatography (column: SunFile™ Prep C18 OBD™ 5 μm 30 mm×150 mm); mobile phase: A=acetonitrile, B=water; gradient: 1%-25% over 8 minutes) to obtain 3-(7-cyclopropyl-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (64.5 mg, yield: 25.9%).

[0406] LC-MS, M / Z(ESI+):460.2[M+H] +

[0407] 1 H NMR (400MHz, CDCl3) δ7.53 (s, 1H), 7.49 (d, J = 7.9Hz, 1H), 7.39 (d, J = 7.9Hz, 1H),6.83(s,1H),5.61(s,2H),4.73(dt,J=18.4,6.3Hz,4H),3.76–3.70(m,1 H),3.54(s,2H),3.11(t,J=5.9Hz,2H),2.74(t,J=6.0Hz,2H),2.58(s,3H),2 .19(ddd,J=13.6,8.4,5.3Hz,1H),1.19–1.11(m,2H),0.84(q,J=5.1Hz,2H).

[0408] Example 2: Preparation of target compound I-9

[0409] 3-(7,8-dimethyl-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0410] The synthetic route of target compound I-9 is as follows:

[0411] Step 1: 3-(6-chloro-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0412] 3,6-Dichloro-4,5-dimethylpyridazine (1.5 g, 8.5 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (1.2 g, 8.5 mmol) were added sequentially to 10 mL of n-butanol. The mixture was heated under reflux under argon for 4 hours. The solvent was evaporated to dryness, and the solid was slurried with 20 mL of dichloromethane for half an hour. The insoluble matter was filtered, and the organic phase was concentrated. The residue was purified by silica gel chromatography (PE / EA (V / V) = 1 / 1) to provide 3-(6-chloro-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (1.2 g, yield: 52.9%).

[0413] Step 2: 3-(7,8-dimethyl-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0414] At room temperature, 3-(6-chloro-7,8-dimethyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.57 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (125 mg, 0.57 mmol) and cesium carbonate (370 mg, 1.14 mmol) were dissolved in acetonitrile (6 mL). The reaction solution was then reacted at 50 ° C for 16 hours. LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, which was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, followed by extraction with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The organic phase was filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by reverse-phase high performance liquid chromatography (chromatographic column: SunFile™ Prep C18 OBD™ 5 μm 30 mm×150 mm; mobile phase: A=acetonitrile, B=water; gradient: 1%-25% over 8 minutes) to obtain 3-(7,8-dimethyl-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (31.6 mg, yield: 12%).

[0415] LC-MS, M / Z(ESI+):448.2[M+H] +

[0416] 1 H NMR (400MHz, CDCl3) δ7.46(d,J=7.9Hz,1H),7.39(d,J=7.9Hz,1H),6.84(s,1H),5.55(s,2H),4.74(dt,J=17.8,6.3Hz,4 H),3.78–3.70(m,1H),3.54(s,2H),3.11(t,J=6.0Hz,2H),2.74(t,J=6.0Hz,2H),2.69(s,3H),2.57(s,3H),2.32(s,3H).

[0417] Example 3: Preparation of target compound I-11

[0418] 5-Cyclopropyl-3-(8-methoxy-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole

[0419] The synthetic route of target compound I-11 is as follows:

[0420] Step 1: 5-cyclopropylisoxazole-3-carboxylic acid hydrazide

[0421] Ethyl 5-cyclopropylisoxazole-3-carboxylate (5.00 g, 29.94 mmol) was dissolved in ethanol (25 mL), followed by the addition of hydrazine hydrate (4.0 mL, 80%). After complete addition, the reaction mixture was incubated at 100°C under nitrogen for 2 hours. LC-MS indicated completion of the reaction. The reaction mixture was concentrated under reduced pressure to afford the crude product, which was washed with dichloromethane (50 mL) and filtered to obtain a filter cake. The filter cake was dried to afford 5-cyclopropylisoxazole-3-carboxylic acid hydrazide (4.2 g, 83% yield).

[0422] Step 2: 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-cyclopropylisoxazole

[0423] 3,6-Dichloro-4-methoxypyridazine (4.23 g, 23.8 mmol) and 5-cyclopropylisoxazole-3-carboxylic acid hydrazide (4.0 g, 23.8 mmol) were added sequentially to 30 mL of n-butanol. The mixture was heated under reflux under argon for 4 hours. The solvent was evaporated to dryness, and the solid was slurried with 40 mL of dichloromethane for half an hour. The insoluble material was filtered, and the organic phase was concentrated. The residue was purified by silica gel chromatography (PE / EA (V / V) = 1 / 1) to provide 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-cyclopropylisoxazole (190 mg, yield: 2.5%).

[0424] Step 3: 5-cyclopropyl-3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole

[0425] At room temperature, 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-cyclopropylisoxazole (150 mg, 0.51 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (113 mg, 0.51 mmol) and cesium carbonate (335 mg, 1.14 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, which was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, followed by extraction with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The organic phase was filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by reverse-phase high performance liquid chromatography (column: SunFile™ Prep C18 OBD™ 5 μm 30 mm×150 mm); mobile phase: A=acetonitrile, B=water; gradient: 1%-25% over 8 minutes) to obtain 5-cyclopropyl-3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole (45 mg, yield: 25.9%).

[0426] LC-MS, M / Z(ESI+):476.2[M+H] +

[0427] 1 H NMR (400MHz, CDCl3) δ7.44(d,J=7.9Hz,1H),7.37(d,J=7.9Hz,1H),6.75(s,1H),6.21(s,1H),5.52(s,2H), 4.73(dt,J=18.4,6.4Hz,4H),4.12(s,3H),3.76–3.69(m,1H),3.53(s,2H),3.11(t,J=6.0Hz,2H),2.73(t, J=6.0Hz,2H),2.18(ddd,J=16.9,8.3,5.1Hz,1H),1.18–1.08(m,4H).

[0428] Example 4: Preparation of target compound I-8

[0429] 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one

[0430] The synthetic route of target compound I-8 is as follows:

[0431] Step 1: Synthesis of tert-butyl 3-oxopiperazine-1-carboxylate

[0432] At room temperature, piperazin-2-one (10.0 g, 0.1 mol) was dissolved in DCM (100 mL), followed by the addition of di-tert-butyl dicarbonate (21.8 g, 0.1 mol). After complete addition, the reaction mixture was allowed to react at room temperature for 2 hours. LCMS indicated the reaction was complete. Water (200 mL) was added to the reaction mixture, which was then extracted three times with dichloromethane (100 mL). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated to dryness. The crude product was isolated by column chromatography (PE / EtOAc (v / v) = 4 / 1) to afford tert-butyl 3-oxopiperazine-1-carboxylate (18 g).

[0433] Step 2: Synthesis of tert-butyl 4-(4-methoxybenzyl)-3-oxopiperazine-1-carboxylate

[0434] Under ice-cooling, tert-butyl 3-oxopiperazine-1-carboxylate (5 g, 0.25 mol) was dissolved in DMF (60 mL). Sodium hydride (1.8 g, 0.37 mol) was then slowly added to the reaction mixture. The mixture was stirred for 30 minutes after addition. 1-(Chloromethyl)-4-methoxybenzene (5.1 g, 0.3 mol) was then added dropwise to the reaction mixture. The mixture was then stirred at room temperature for 2 hours. LCMS indicated that the reaction was complete. 50 mL of water was added to the reaction mixture to quench the reaction. Water (200 mL) was then added to the reaction mixture, and the mixture was extracted three times with dichloromethane (100 mL). The organic phases were combined, washed five times with water (100 mL), and then washed with saturated brine (100 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography to give tert-butyl 4-(4-methoxybenzyl)-3-oxopiperazine-1-carboxylate (6 g).

[0435] Step 3: Synthesis of 1-(4-methoxybenzyl)piperazin-2-one

[0436] tert-Butyl 4-(4-methoxybenzyl)-3-oxopiperazine-1-carboxylate (6.0 g, 18.75 mmol) was dissolved in dioxane (4 M hydrochloric acid, 30 mL) at room temperature. The reaction mixture was allowed to react for 2 hours. After completion of the reaction, as monitored by LCMS, the reaction mixture was concentrated to afford 1-(4-methoxybenzyl)piperazin-2-one (hydrochloride, 4 g), which was used directly in the next step without purification.

[0437] Step 4: Synthesis of methyl 6-(4-(4-methoxybenzyl)-3-oxopiperazin-1-yl)pyridazine-3-carboxylate

[0438] Methyl 6-chloropyridazine-3-carboxylate (1.25 g, 7.26 mmol) was dissolved in dioxane (20 mL) at room temperature. 1-(4-methoxybenzyl)piperazin-2-one (hydrochloride, 1.6 g, 7.27 mmol), Pd2(dba)3 (665 mg, 0.72 mmol), Xantphos (420 mg, 0.72 mmol), and cesium carbonate (3.54 g, 10.9 mmol) were then added sequentially. The mixture was reacted at 100°C under nitrogen for 16 hours. LCMS indicated the reaction was complete. The reaction solution was concentrated to obtain a crude product, and water (50 mL) was added to the reaction solution, followed by extraction three times with dichloromethane (30 mL). The organic phases were combined, washed with saturated brine (40 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (EtOAc / PE (V / V) = 1:1) to give methyl 6-(4-(4-methoxybenzyl)-3-oxopiperazin-1-yl)pyridazine-3-carboxylate (0.78 mg).

[0439] Step 5: Synthesis of 4-(6-(hydroxymethyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one

[0440] Methyl 6-(4-(4-methoxybenzyl)-3-oxopiperazin-1-yl)pyridazine-3-carboxylate (0.78 mg, 2.19 mmol) was dissolved in tetrahydrofuran / ethanol (V / V = 1 / 1) (10 mL) under ice-cooling conditions, followed by the addition of sodium borohydride (166.4 mg, 4.38 mmol) and calcium chloride (486.1 mg, 4.38 mmol). The reaction mixture was allowed to react at room temperature for 16 hours, and LCMS indicated the reaction was complete. The reaction mixture was filtered to obtain a filtrate, which was concentrated to obtain the crude product, which was directly separated by column chromatography (DCM / MeOH (V / V) = 10:1) to afford 4-(6-(hydroxymethyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (0.51 g).

[0441] Step 6: Synthesis of 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one

[0442] At room temperature, 3-(6-chloro-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (403 mg, 1.52 mmol), 4-(6-(hydroxymethyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (500 mg, 1.52 mmol) and cesium carbonate (990 mg, 3.04 mmol) were dissolved in acetonitrile (10 mL). The reaction solution was then reacted at 50 ° C for 16 hours. LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and the mixture was extracted three times with dichloromethane (10 mL). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (DCM / MeOH (V / V) = 15 / 1) to give 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (220 mg).

[0443] Step 7: Synthesis of 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one

[0444] At room temperature, 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (220 mg, 0.39 mmol) was dissolved in toluene (6 mL), and trifluoromethanesulfonic acid (0.5 mL) was added. The reaction was then placed at 110° C. for 2 hours. LCMS detected that the reaction was complete, and the reaction solution was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted three times with dichloromethane (10 mL). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by high performance liquid phase to obtain 4-(6-(((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one (6.0 mg)

[0445] LC-MS, M / Z(ESI+):438.1[M+H] +

[0446] 1H NMR (400 MHz, DMSO- d6 )δ8.15(s,1H),7.75(s,1H),7.72(d,J=9.6Hz,1H),7.30(d,J=9.6Hz,1H),7.04(s,1H),5 .59(s,2H),4.11(s,2H),3.96(s,3H),3.86–3.80(m,2H),3.30–3.29(m,2H),2.57(s,3H).

[0447] Example 5: Preparation of target compound I-12

[0448] 5-methyl-3-(6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole

[0449] The synthetic route of target compound I-12 is as follows:

[0450] Step 1: Synthesis of 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0451] 3,6-Dichloropyridazine (1.0 g, 7.0 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (1.05 g, 7.0 mmol) were added sequentially to 10 mL of n-butanol. The mixture was heated under reflux under argon for 4 hours. The solvent was evaporated to dryness, and the solid was slurried with 10 mL of dichloromethane for half an hour. The insoluble material was filtered, and the organic phase was concentrated. The residue was purified by silica gel chromatography (PE / EtOAc (V / V) = 1 / 1) to provide 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (370 mg).

[0452] Step 2: Synthesis of 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole

[0453] At room temperature, 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.63 mmol), (6-(oxane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (140 mg, 0.63 mmol) and cesium carbonate (414.8 mg, 1.12 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and the mixture was extracted three times with dichloromethane (10 mL). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by high performance liquid phase to obtain 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole (90 mg).

[0454] LC-MS, M / Z(ESI+):419.2[M+H] +

[0455] 1 H NMR (400MHz, CDCl3) δ8.07(d,J=9.8Hz,1H),7.46(d,J=7.8Hz,1H),7.39(d,J=7.9Hz,1H),6.97(d,J=9.8Hz,1H),6.84(s,1H),5.54( s,2H),4.72(dt,J=18.4,6.3Hz,4H),3.72(p,J=6.4Hz,1H),3.53(s,2H),3.10(t,J=5.9Hz,2H),2.73(t,J=6.0Hz,2H),2.58(s,3H).

[0456] Example 6: Preparation of target compound I-14

[0457] 3-(8-methoxy-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0458] The synthetic route of target compound I-14 is as follows:

[0459] Step 1: Synthesis of 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0460] 3,6-Dichloro-4-methoxy-pyridyl (9.9 g, 55.6 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (7.8 g, 55.6 mmol) were added sequentially to 50 mL of n-butanol. The mixture was heated under reflux under argon for 4 hours. The solvent was evaporated to dryness, and the solid was slurried with 50 mL of dichloromethane for half an hour. The insoluble material was filtered, and the organic phase was concentrated. The residue was purified by silica chromatography (PE / EtOAc = 1 / 4, v / v) to obtain a crude product (2.7 g).

[0461] Step 2: Synthesis of 3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0462] At room temperature, 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.51 mmol), (6-(oxane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (113 mg, 0.51 mmol) and cesium carbonate (333 mg, 1.01 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and the mixture was extracted three times with dichloromethane (10 mL). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by high performance liquid phase to obtain 3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (30 mg).

[0463] LC-MS, M / Z(ESI):450.2[M+H] +

[0464] 1H NMR (400MHz, CDCl3) δ7.47(d,J=7.8Hz,1H),7.39(d,J=7.8Hz,1H),7.26(s,1H),6.79(s,1H),5.57(s,2H),4.80-4.6 3(m,4H),4.00(s,3H),3.71(t,J=6.6Hz,1H),3.52(s,2H),3.08(t,J=5.9Hz,2H),2.71(t,J=6.1Hz,2H),2.55(s,3H)

[0465] Example 7: Preparation of target compound I-15

[0466] 3-(7-methoxy-6-(1-(6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0467] The synthetic route of target compound I-15 is as follows:

[0468] Step 1: Synthesis of 1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethan-1-one hydrochloride

[0469] Dissolve tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.85 g, 3.16 mmol) in anhydrous dioxane (10 mL). Then weigh tributyl(1-ethoxyethylene)tin (1.37 g, 3.80 mmol), triethylamine (0.96 g, 9.49 mmol), and dichlorobistriphenylphosphine palladium (0.22 g, 0.32 mmol). Evacuate and replace with nitrogen three times. The reaction mixture was then incubated at 100°C under nitrogen for 16 hours. TLC (PE:EA (V / V) = 1:1) indicated completion of the reaction. The reaction mixture was cooled to room temperature, diluted with water (10 mL), and extracted three times with EtOAc (20 mL). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated to dryness. The crude product was separated by normal-phase silica gel column chromatography (PE / EtOAc (V / V) = 0%-50%) to afford tert-butyl 2-(1-ethoxyvinyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate. The column chromatography product was then concentrated under reduced pressure to dryness, diluted with anhydrous dioxane (10 mL), and then 6N HCl (5 mL) was added. The reaction mixture was stirred at room temperature for 30 min. TLC (PE:EA (V / V) = 1:1) indicated the reaction was complete. The reaction solution was directly concentrated under reduced pressure and dried to give 1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethan-1-one hydrochloride (0.60 g, crude product), which was directly used in the next step.

[0470] Step 2: Synthesis of tert-butyl 2-acetyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate

[0471] Dissolve 1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethan-1-one hydrochloride (0.60 g, 2.41 mmol) in anhydrous dichloromethane (10 mL) in an ice bath. Then, weigh triethylamine (1.22 g, 12.04 mmol), di-tert-butyl dicarbonate (0.79 g, 3.61 mmol), and N,N-dimethylpyridin-4-amine (29.42 mg, 0.24 mmol) into the solution. The reaction mixture was allowed to react at room temperature for 10 hours. TLC (PE:EA (V / V) = 3:1) indicated the reaction was complete. Water (15 mL) was added to the reaction solution, and the mixture was extracted three times with EtOAc (20 mL). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous Na2SO4. The mixture was filtered, concentrated under reduced pressure and spin-dried. The crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 0%-40%) to give tert-butyl 2-acetyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.32 g).

[0472] Step 3: Synthesis of tert-butyl 2-(1-hydroxyethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate

[0473] Under ice-cooling conditions, tert-butyl 2-acetyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.32 g, 4.38 mmol) was dissolved in methanol (5 mL), and sodium borohydride (65.71 mg, 1.74 mmol) was added portionwise. The reaction mixture was allowed to react at room temperature for 2 hours. TLC (PE:EA = 3:1) indicated completion of the reaction. Saturated NH4Cl solution (5 mL) was added to the reaction mixture, and the mixture was extracted three times with EtOAc (10 mL). The organic phase was washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to dryness. The crude product was separated by normal phase silica gel column chromatography (PE / EtOAc (V / V) = 0%-50%) to obtain tert-butyl 2-(1-hydroxyethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.25 g).

[0474] Step 4: Synthesis of tert-butyl 2-(1-((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)ethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate

[0475] At room temperature, tert-butyl 2-(1-hydroxyethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.14 g, 0.50 mmol) was dissolved in acetonitrile (3 mL). 3-(6-chloro-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (133.61 mg, 0.50 mmol) and cesium carbonate (0.49 g, 1.50 mmol) were then added. The reaction mixture was incubated at 60°C for 10 minutes. TLC (PE:EA (V / V) = 1:1) indicated the reaction was complete. Water (30 mL) was added to the reaction solution, and the mixture was extracted three times with EtOAc (10 mL). The organic phase was washed with saturated brine (5 mL), dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure and spin-dried. The crude product was separated by normal phase silica gel column chromatography (PE / EtOAc = 0%-50%) to give tert-butyl 2-(1-((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)ethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.32 g).

[0476] Step 5: Synthesis of 3-(7-methoxy-6-(1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole hydrochloride

[0477] Under ice-cooling, tert-butyl 2-(1-((7-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)ethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (0.32 g) was dissolved in ethyl acetate (3 mL), followed by the addition of 4 M ethyl acetate hydrochloride (6 mL). After complete addition, the reaction mixture was incubated under ice-cooling for 1 minute. TLC (PE:EA (V / V) = 1:1) indicated completion of the reaction. The reaction mixture was then concentrated under reduced pressure and dried to dryness to afford 3-(7-methoxy-6-(1-(5,6,7,8-tetrahydro-1,6-naphthyridine-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole hydrochloride (0.43 g, crude product).

[0478] Step 6: Synthesis of 3-(7-methoxy-6-(1-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0479] Under ice, 3-(7-methoxy-6-(1-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole hydrochloride (0.43 g, 0.90 mmol) was dissolved in dichloroethane (5 mL). Triethylamine (0.19 g, 1.80 mmol) was then added. The mixture was stirred for 30 minutes. 3-Oxetanone (70.96 mg, 0.98 mmol), sodium acetate borohydride (0.28 g, 1.34 mmol), and acetic acid (5.38 mg, 0.09 mmol) were then added in sequence. After the addition was complete, the reaction mixture was allowed to warm to room temperature and stirred for 16 hours. LCMS monitoring indicated the reaction was complete. Dichloromethane (10 mL) was added to the reaction solution, and the mixture was washed sequentially with water (5 mL) and saturated brine (5 mL). The organic phase was concentrated under reduced pressure and dried. The residue was separated by normal phase silica gel column chromatography (PE / EtOAc = 0%-50%) to give 3-(7-methoxy-6-(1-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (0.22 g).

[0480] LC-MS, M / Z(ESI):464.2[M+H] +

[0481] 1 H NMR (400MHz, CDCl3): δ7.39(d,1H),7.31(d,1H),7.18(s,1H),6.77(s,1H),6.23-6.18(m,1H),4.75-4.68(m,4H) ),4.01(s,3H),3.73-3.66(m,1H),3.48(s,2H),3.10-3.07(m,2H),2.71-2.68(m,2H),2.57(s,3H),1.81(d,3H)

[0482] Example 8: Preparation of target compound I-17

[0483] 3-(5-methylisoxazol-3-yl)-N-(6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide

[0484] The synthetic route of target compound I-17 is as follows:

[0485] Step 1: Synthesis of methyl 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylate

[0486] Methyl 6-chloropyridazine-3-carboxylate (600 mg, 3.48 mmol) and 5-methylisoxazole-3-carboxylic acid hydrazide (490 mg, 3.48 mmol) were added sequentially to 4 mL of n-butanol, and the mixture was heated under reflux for 4 hours under nitrogen protection. The reaction system was cooled to room temperature and concentrated. The crude product was purified by silica gel column (PE / EA (V / V) = 3 / 1) to give methyl 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylate (580 mg).

[0487] LC-MS, M / Z(ESI):260.1[M+H] +

[0488] Step 2: Synthesis of 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylic acid

[0489] 3-(5-Methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylic acid methyl ester (580 mg, 2.23 mmol) and lithium hydroxide monohydrate (460 mg, 11.1 mmol) were added sequentially to 10 mL of a mixed solvent of tetrahydrofuran and water (V / V=1 / 1), and the reaction was carried out at 50°C for 4 hours. After the reaction system was cooled to room temperature, the pH was adjusted to 5-6 with 1N hydrochloric acid, and the mixture was extracted three times with dichloromethane (10 mL). The organic phase was collected and concentrated to obtain a crude product, which was then purified by silica gel column chromatography (DCM / MeOH (V / V)=30 / 1) to give 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylic acid (260 mg).

[0490] LC-MS, M / Z(ESI):246.1[M+H] +

[0491] Step 3: Synthesis of 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide

[0492] 3-(5-Methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxylic acid (260 mg, 1.05 mmol) was dissolved in anhydrous DMF (5 mL), and triethylamine (1.0 g, 10.5 mmol), HATU (600 mg, 1.5 mmol), and ammonium chloride (340 mg, 6.30 mmol) were added sequentially. The mixture was allowed to react at room temperature for 16 hours. Water (10 mL) was added to the reaction system, and the mixture was extracted twice with dichloromethane (10 mL). The organic phase was collected and concentrated to obtain the crude product, which was then purified on a silica gel column (DCM / MeOH (v / v) = 30 / 1) to afford 3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide (140 mg).

[0493] LC-MS, M / Z(ESI):245.1[M+H] +

[0494] Step 4: Synthesis of tert-butyl 2-(3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamido)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate

[0495] 3-(5-Methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide (140 mg, 0.57 mmol) was dissolved in anhydrous dioxane (3 mL), and tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (183 mg, 0.68 mmol), cesium carbonate (370 mg, 1.15 mmol), Pd2(dba)3 (90 mg, 0.1 mmol), and Xantphos (60 mg, 0.1 mmol) were added in sequence. The mixture was reacted at 110 ° C for 16 hours under nitrogen protection. The reaction mixture was concentrated and purified by silica gel column chromatography (DCM / MeOH (V / V) = 30 / 1) to give tert-butyl 2-(3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamido)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (80 mg).

[0496] LC-MS, M / Z(ESI):477.2[M+H] +

[0497] Step 5: Synthesis of 3-(5-methylisoxazol-3-yl)-N-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide hydrochloride

[0498] Dissolve tert-butyl 2-(3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamido)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (80 mg, 0.18 mmol) in tetrahydrofuran (2 mL). Add 4N dioxane hydrochloride (0.5 mL) and react at room temperature for 4 hours. The reaction mixture was concentrated to obtain a crude product (105.3 mg) which was used directly in the next step.

[0499] LC-MS, M / Z(ESI):377.1[M+H] +

[0500] Step 6: Synthesis of 3-(5-methylisoxazol-3-yl)-N-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide

[0501] 3-(5-Methylisoxazol-3-yl)-N-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide hydrochloride (105.3 mg crude product, 0.18 mmol) was dissolved in 1,2-dichloroethane (3 mL), and triethylamine (36.6 mg, 0.36 mmol) was added. The mixture was stirred at room temperature for 15 min, and then 3-oxetanone (26.1 mg, 0.36 mmol) was added. The reaction was stirred for 1 hour, and then sodium acetate borohydride (76.2 mg, 0.36 mmol) and a drop of acetic acid were added. The reaction was allowed to react at room temperature overnight. Water (5 mL) was added to the reaction and extracted three times with dichloromethane (5 mL). The organic phase was collected and concentrated, separated and purified by Pre-HPLC, and dried to give 3-(5-methylisoxazol-3-yl)-N-(6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine-6-carboxamide (21.6 mg).

[0502] LC-MS, M / Z(ESI):433.2[M+H] +

[0503] 1 H NMR (400MHz, CDCl3) δ8.38(d,J=9.8Hz,1H),8.13(dd,J=9.0,2.4Hz,2H),7.44(d,J=8.4Hz,1H),6.90(s,1H),4.74( dt,J=14.8,6.2Hz,4H),3.79–3.69(m,1H),3.53(s,2H),3.04(t,J=6.0Hz,2H),2.72(t,J=6.0Hz,2H),2.62(s,3H).

[0504] Example 9: Preparation of target compounds I-19, I-19A and I-19B

[0505] 3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol

[0506] (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol

[0507] (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol

[0508] The synthetic routes of target compounds I-19, I-19A and I-19B are as follows:

[0509] Step 1: 6-(tert-butyl) 2-methyl 7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate

[0510] At room temperature, tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (5.00 g, 18.65 mmol) and Pd(dppf)Cl2 (1.36 g, 1.86 mmol) were dissolved in 40 mL of a mixed solution of methanol / triethylamine (V / V=8 / 1). The reaction solution was heated at 60°C under the protection of carbon monoxide for 16 hours. LCMS showed that the reaction was complete. The reaction solution was concentrated to give a crude product, water (50 mL) was added to the crude product, and then extracted three times with dichloromethane (30 mL), the organic phases were combined, washed with saturated brine (30 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (EtOAc / PE (V / V) = 1:4) to give 7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylic acid 6-(tert-butyl) 2-methyl ester (5.1 g).

[0511] LC-MS, M / Z(ESI):293.1[M+H] +

[0512] Step 2: Synthesis of tert-butyl 2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate

[0513] Under ice-cooling conditions, 6-(tert-butyl)-2-methyl-7,8-dihydro-1,6-naphthyridine-2,6(5H)-dicarboxylate (2 g, 6.8 mmol) was dissolved in 30 mL of a mixture of tetrahydrofuran / ethanol (v / v = 1 / 1). Sodium borohydride (520 mg, 13.6 mmol) and calcium chloride (1.52 g, 13.6 mmol) were then added. The reaction mixture was allowed to react at room temperature for 16 hours, and LCMS indicated the reaction was complete. The reaction mixture was filtered to obtain a filtrate, which was concentrated to afford the crude product, which was directly separated by column chromatography (DCM / MeOH (v / v) = 10:1) to afford tert-butyl-2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (1.2 g).

[0514] LC-MS, M / Z(ESI):265.2[M+H] +

[0515] Step 3: Synthesis of tert-butyl 2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate

[0516] At room temperature, 3-(6-chloro-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (501 mg, 1.89 mmol), tert-butyl 2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (500 mg, 1.89 mmol) and cesium carbonate (1.23 g, 3.78 mmol) were dissolved in acetonitrile (20 mL). The reaction solution was reacted at 50 ° C for 16 hours. LCMS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and the mixture was extracted three times with dichloromethane (20 mL). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (DCM / MeOH=15 / 1, V / V) to give tert-butyl 2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (580 mg).

[0517] LC-MS, M / Z(ESI):394.2[M+H-100] +

[0518] Step 4: Synthesis of 3-(8-methoxy-6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0519] Tert-butyl 2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (580 mg, 1.17 mmol) was dissolved in hydrochloric acid / dioxane (10 mL, 4 M) at room temperature and allowed to react for 2 hours. LCMS indicated that the reaction was complete, and the reaction solution was concentrated to afford 3-(8-methoxy-6-((5,6,7,8-tetrahydro-1,6-naphthyridine-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (400 mg, crude), which was used directly in the next step without purification.

[0520] LC-MS, M / Z(ESI):394.2[M+H] +

[0521] Step 5: Synthesis of 3-(6-((6-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0522] 3-(8-Methoxy-6-((5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (400 mg, 1.017 mmol) and 2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (158 mg, 1.22 mol) were dissolved in 1,2-dichloroethane (10 mL) at room temperature. The reaction mixture was stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (772 mg, 3.66 mmol) was then added portionwise and the reaction mixture was stirred at room temperature for 16 hours. LCMS indicated the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (20 mL) was added to the crude product, and the mixture was extracted three times with dichloromethane (20 mL). The organic phases were combined, washed with saturated brine (40 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (DCM / MeOH (V / V) = 15:1) to give 3-(6-((6-((2,2-dimethyl-1,3-dioxolane-4-yl)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (450 mg).

[0523] LC-MS, M / Z(ESI):508.2[M+H] +

[0524] Step 6: 3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol

[0525] On an ice bath, 3-(6-((6-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-8-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (450 mg, 88.7 mmol) was dissolved in methanol (10 mL). 3N hydrochloric acid (5 mL) was then added dropwise, and the mixture was stirred at room temperature for 2 hours. LCMS indicated that the reaction was complete. The reaction solution was concentrated to obtain a crude product, which was separated by high performance liquid phase to give 3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol (110 mg).

[0526] LC-MS, M / Z(ESI):468.2[M+H] +

[0527] Step 7: Synthesis of (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol and (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol

[0528] (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol

[0529] (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,2-diol

[0530] 3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol (110 mg) was chirally resolved by SFC under the following conditions: column: Chiralpak AD-3 50*4.6mm ID, 3μm; solvent: A=CO2, B=0.05% volume diethylamine in ethanol.

[0531] Peak 1 was separated and concentrated to give compound (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol or (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol (74.8 mg, ee>99%, SFC retention time: 1.825 min).

[0532] LC-MS, M / Z(ESI):468.2[M+H] +

[0533] 1 H NMR (400MHz, DMSO) δ7.53(d,J=7.9Hz,1H),7.39(d,J=7.8Hz,1H),7.04(s,1H),6.74(s,1H),5.44(s,2H),4.58–4.45(m,2H),4.1 2(s,3H),3.73–3.68(m,1H),3.66(s,2H),2.93–2.87(m,2H),2.87–2.79(m,2H),2.61–2.55(m,4H),2.43(dd,J=12.7,7.0Hz,1H).

[0534] Peak 2 was separated and concentrated to give compound (2R)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol or (2S)-3-(2-(((8-methoxy-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-yl)propane-1,2-diol (9.2 mg, ee=80%, SFC retention time: 2.496 min).

[0535] LC-MS, M / Z(ESI):468.2[M+H] +

[0536] 1H NMR (400MHz, DMSO) δ7.53(d,J=7.9Hz,1H),7.39(d,J=7.8Hz,1H),7.04(s,1H),6.74(s,1H),5.44(s,2H),4.58–4.45(m,2H),4.1 2(s,3H),3.73–3.68(m,1H),3.66(s,2H),2.93–2.87(m,2H),2.87–2.79(m,2H),2.61–2.55(m,4H),2.43(dd,J=12.7,7.0Hz,1H).

[0537] The SFC retention time of compound I-19A was 1.825 min, and the SFC retention time of compound I-19B was 2.496 min.

[0538] Example 10: Preparation of target compound I-21

[0539] 5-Cyclopropyl-3-(8-methoxy-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole

[0540] The synthetic route of target compound I-21 is as follows:

[0541] Step 1: Synthesis of 5-cyclopropyl-3-(8-methoxy-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole

[0542] 6-Chloro-3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile (320 mg, 1.23 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (300 mg, 1.35 mmol), and potassium carbonate (254 mg, 1.84 mmol) were added sequentially to anhydrous acetonitrile (8 mL), and the reaction system was reacted at room temperature for 16 hours. Water (10 mL) was added to the reaction, and the mixture was extracted three times with ethyl acetate (10 mL). The organic phase was collected and concentrated to obtain a crude product. The crude product was first quickly purified by silica gel column to obtain a crude product, and then separated and purified by Pre-HPLC and dried to give 3-(5-methylisothiazol-3-yl)-6-((6-(oxabutane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-8-carbonitrile (61.5 mg).

[0543] LC-MS, M / Z(ESI):445.2[M+H] +

[0544] 1 H NMR (400MHz, CDCl3) δ7.46(d,J=7.8Hz,1H),7.39(d,J=7.8Hz,1H),7.34(s,1H),6.84(s,1H),5.57(s,2H),4.72(d t,J=21.0,6.4Hz,4H),3.76–3.67(m,1H),3.53(s,2H),3.08(t,J=5.8Hz,2H),2.72(t,J=6.0Hz,2H),2.59(s,3H).

[0545] Example 11: Preparation of target compound I-22

[0546] 3-(5-methylisoxazol-3-yl)-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile

[0547] The synthetic route of target compound I-22 is as follows:

[0548] Step 1: Synthesis of 3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile

[0549] 6-Chloro-3-(5-methylisothiazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile (1.0 g, 3.84 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (930 mg, 4.22 mmol), and potassium carbonate (800 mg, 5.76 mmol) were added sequentially to anhydrous acetonitrile (20 mL), and the reaction system was reacted at 50 ° C for 2 hours. After cooling to room temperature, water (20 mL) was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate (20 mL). The organic phase was collected and concentrated to obtain a crude product. The crude product was first quickly purified by silica gel column to obtain a crude product, and then separated and purified by Pre-HPLC and dried to obtain 3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine-7-carbonitrile (100.2 mg).

[0550] LC-MS, M / Z(ESI):445.2[M+H] +

[0551] 1 H NMR (400MHz, CDCl3) δ8.56(s,1H),7.51(d,J=8.0Hz,1H),7.44(d,J=8.0Hz,1H),6.87(s,1H),5.65(s,2H),4.74(dt ,J=15.2,6.4Hz,4H),3.76(d,J=6.4Hz,1H),3.57(s,2H),3.11(t,J=5.8Hz,2H),2.76(t,J=6.0Hz,2H),2.60(s,3H).

[0552] Example 12: Preparation of target compound I-24

[0553] 3-(6-((6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0554] The synthetic route of target compound I-24 is as follows:

[0555] Step 1: Synthesis of methyl 6-methylpyridazine-3-carboxylate

[0556] 3-Chloro-6-methylpyridazine (6.0 g, 46.8 mmol) and Pd(dppf)Cl2 (3.42 g, 4.68 mmol) were dissolved in 60 mL of a mixture of methanol and triethylamine (V / V = 8 / 1) at room temperature. The reaction mixture was heated at 60°C under carbon monoxide protection for 16 hours. LCMS showed that the reaction was complete. The reaction mixture was concentrated to obtain a crude product. Water (50 mL) was added to the crude product, and the mixture was extracted three times with dichloromethane (30 mL). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness. The crude product was separated by column chromatography (EtOAc / PE (V / V) = 1:4) to obtain methyl 6-methylpyridazine-3-carboxylate (4.5 g).

[0557] LC-MS, M / Z(ESI):152.1[M+H] +

[0558] Step 2: Synthesis of methyl 6-(bromomethyl)pyridazine-3-carboxylate

[0559] Methyl 6-methylpyridazine-3-carboxylate (4.5 g, 29.6 mmol), N-bromosuccinimide (6.3 g, 35.5 mmol), and azobisisobutyronitrile (0.48 g, 2.96 mmol) were dissolved in DMF (60 mL) at room temperature and reacted at 80°C under nitrogen for 45 minutes. LCMS indicated the reaction was complete. The reaction solution was added to water (60 mL) and extracted three times with dichloromethane (40 mL). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated to dryness. The crude product was purified by column chromatography (PE / EtOAc (V / V) = 1 / 1) to afford methyl 6-(bromomethyl)pyridazine-3-carboxylate (2.5 g).

[0560] LC-MS, M / Z(ESI):232.0[M+H] +

[0561] Step 3: Synthesis of 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylic acid

[0562] 2-Methoxyethane-1-ol (925 mg, 12.1 mmol) was dissolved in THF (10 mL) under an ice bath. Sodium hydroxide (292 mg, 12.1 mmol, 60% purity) was then slowly added to the reaction mixture. After stirring for 10 minutes, methyl 6-(bromomethyl)pyridazine-3-carboxylate (1.4 g, 6.0 mmol) was added and the mixture was allowed to react at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was quenched with 10 mL of methanol and concentrated to afford the crude product. The crude product was purified by column chromatography (DCM / MeOH (V / V) = 10 / 1) to afford 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylic acid (550 mg).

[0563] LC-MS, M / Z(ESI):213.1[M+H] +

[0564] Step 4: Synthesis of methyl 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylate

[0565] 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylic acid (550 mg, 2.6 mmol) was dissolved in methanol (10 mL) at room temperature, followed by the dropwise addition of concentrated sulfuric acid (0.5 mL). The reaction mixture was allowed to react at 60°C for 2 hours. LCMS indicated that the reaction was complete, and the reaction mixture was concentrated to obtain a crude product. The pH of the crude product was adjusted to approximately 7-8 with saturated sodium bicarbonate solution, followed by extraction three times with dichloromethane (20 mL). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated to dryness. The crude product was separated by column chromatography (PE / EtOAc (V / V) = 1 / 1) to afford methyl 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylate (230 mg).

[0566] LC-MS, M / Z(ESI):227.1[M+H] +

[0567] Step 5: Synthesis of (6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methanol

[0568] Methyl 6-((2-methoxyethoxy)methyl)pyridazine-3-carboxylate (230 mg, 1.07 mmol) was dissolved in 10 mL of a mixture of tetrahydrofuran / ethanol (V / V = 1 / 1) under ice-cooling conditions. Sodium borohydride (77.3 mg, 2.03 mmol) and calcium chloride (225.9 mg, 2.03 mmol) were then added, respectively. The reaction mixture was allowed to react at room temperature for 16 hours. LCMS indicated the reaction was complete. The reaction mixture was filtered to obtain a filtrate, which was concentrated to obtain the crude product, which was directly separated by column chromatography (DCM / MeOH (V / V) = 10:1) to afford (6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methanol (120 mg).

[0569] LC-MS, M / Z(ESI):199.1[M+H] +

[0570] Step 6: Synthesis of 3-(6-((6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0571] At room temperature, 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (142 mg, 0.60 mmol), (6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methanol (120 mg, 0.60) and cesium carbonate (390 mg, 1.2 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and the mixture was extracted three times with dichloromethane (10 mL). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by high performance liquid phase to obtain 3-(6-((6-((2-methoxyethoxy)methyl)pyridazin-3-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (45.9 mg).

[0572] LC-MS, M / Z(ESI):398.2[M+H] +

[0573] 1H NMR (400MHz, CDCl3) δ8.09(d,J=9.8Hz,1H),8.03(d,J=8.7Hz,1H),7.75(d,J=8.6Hz,1H),6.98(d,J=9.8Hz,1H), 6.82(s,1H),5.82(s,2H),4.92(s,2H),3.76–3.70(m,2H),3.62–3.56(m,2H),3.38(s,3H),2.58(d,J=9.2Hz,3H).

[0574] Example 13: Preparation of target compounds I-15A & I-15B

[0575] 2-((1S)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)ethyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0576] 2-((1R)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl]oxy)ethyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0577] The synthetic routes of target compounds I-15A & I-15B are as follows:

[0578] 3-(7-methoxy-6-(1-(6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)ethoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisothiazolylpyridin-2-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl)-5-methylisothiazolylpyridin-2-yl The oxazole (0.22 g) was separated by SFC using the following methods: column: CHIRALCEL OJ-3I.D. (50*4.6 mm, 3 μm); solvent: A = CO 2 , B = 0.05% by volume diethylamine in ethanol; gradient: 5%-40%.

[0579] Peak 1 was separated and concentrated to give compound 2-((1S)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)ethyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine or 2-((1R)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl]oxy)ethyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (9.52 mg, SFC retention time: 1.53 min).

[0580] 1 H NMR (400MHz, CDCl3): δ7.39 (d, 1H, J1 = 8.0Hz), 7.31 (d, 1H, J1 = 8.0Hz), 7.18 (s, 1H), 6.77 (s, 1H), 6.23-6.18 (m, 1H), 4.75-4.68 (m,4H),4.01(s,3H),3.73-3.66(m,1H),3.48(s,2H),3.10-3.07(m,2H),2.71-2.68(m,2H),2.57(s,3H),1.81(d,3H,J=6.4Hz)

[0581] LC-MS, M / Z(ESI):464.2[M+H] +

[0582] Peak 2 was separated and concentrated to give compound 2-((1S)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)ethyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine or 2-((1R)-1-((7-methoxy-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl]oxy)ethyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (17.85 mg, SFC retention time: 1.68 min).

[0583] 1H NMR (400MHz, CDCl3): δ7.40 (d, 1H, J1 = 8.0Hz), 7.31 (d, 1H, J1 = 8.0Hz), 7.18 (s, 1H), 6.77 (s, 1H), 6.23-6.18 (m, 1H), 4.75-4.68 (m,4H),4.01(s,3H),3.73-3.66(m,1H),3.48(s,2H),3.10-3.07(m,2H),2.71-2.68(m,2H),2.57(s,3H),1.81(d,3H,J=6.4Hz)

[0584] LC-MS, M / Z(ESI):464.2[M+H] +

[0585] The SFC retention time of compound I-15A was 1.53 min, and the SFC retention time of compound I-15B was 1.68 min.

[0586] Example 14: Preparation of target compound I-10

[0587] 3-(7-(3,3-difluoroazetidin-1-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0588] The synthetic route of target compound I-10 is as follows:

[0589] Step 1: Synthesis of 3,6-dichloro-4-(3,3-difluoroazetidin-1-yl)pyridazine

[0590] 3,4,6-Trichloropyridazine (6.0 g, 33.14 mmol) and 3,3-difluoroazetidine hydrochloride (4.7 g, 36.46 mmol) were dissolved in DMF (50 mL). Potassium carbonate (13.7 g, 99.44 mmol) was then added. After complete addition, the reaction mixture was incubated at 40°C for 3 hours. LC-MS indicated the reaction was complete. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed five times with water (30 mL) and twice with saturated brine (30 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (PE / EA = 3 / 1, v / v) to afford 3,6-dichloro-4-(3,3-difluoroazetidin-1-yl)pyridazine (6.1 g, yield: 77.3%).

[0591] Step 2: Synthesis of 3-chloro-4-(3,3-difluoroazetidin-1-yl)-6-hydrazinopyridazine

[0592] 3,6-Dichloro-4-(3,3-difluoroazetidin-1-yl)pyridazine (1.0 g, 4.18 mmol) was dissolved in ethanol (10 mL), followed by the addition of hydrazine hydrate (2 mL). The reaction solution was heated at reflux at 90°C for 9 hours. LC-MS indicated the reaction was complete. The solvent was evaporated to dryness, the organic phase was concentrated, and the residue was purified by silica chromatography (DCM / MeOH = 15 / 1, v / v) to afford 3-chloro-4-(3,3-difluoroazetidin-1-yl)-6-hydrazinopyridazine (370 mg, yield: 36.5%).

[0593] Step 3: Synthesis of 3-(6-chloro-7-(3,3-difluoroazetidin-1-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0594] 3-Chloro-4-(3,3-difluoroazetidin-1-yl)-6-hydrazinopyridazine (370 mg, 1.5 mmol) and 5-methylisoxazole-3-carbaldehyde (200 mg, 1.73 mmol) were dissolved in ethanol (6 mL) at room temperature. The reaction solution was then reacted at 90 °C for 2 hours. LC-MS showed that the reaction was complete. The reaction solution was concentrated to obtain a crude product. DCM (10 mL) was added to the crude product, and then iodophenyldiacetic acid (569 mg, 1.73 mmol) was added to the reaction system. The reaction was allowed to react overnight at room temperature. LC-MS showed that the reaction was complete. The mixture was extracted with dichloromethane (10 mL × 3), and the organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (PE / EtOAc = 1 / 1, v / v) to give 3-(6-chloro-7-(3,3-difluoroazetidine-1-yl)-[1,2,4]triazolo[4,3-b]pyridazine-3-yl)-5-methylisoxazole (330 mg).

[0595] Step 4: Synthesis of 3-(7-(3,3-difluoroazetidine-1-yl)-6-((6-(oxetane-3-yl)-5,6,7-8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole

[0596] At room temperature, 3-(6-chloro-7-(3,3-difluoroazetidin-1-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (150 mg, 0.46 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (101 mg, 0.46 mmol) and cesium carbonate (299.0 mg, 0.92 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, which was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and the mixture was extracted with dichloromethane (10 mL × 3). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by high performance liquid chromatography (HPLC) (column: Titank Prep C18 Bulk 10 μm, 30X The reaction mixture was stirred at 40 mm, mobile phase: solvent A = water + 0.5% ammonia water, solvent B = acetonitrile, gradient: 52% acetonitrile) to separate and obtain 3-(7-(3,3-difluoroazetidin-1-yl)-6-((6-(oxetane-3-yl)-5,6,7-8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (70.5 mg, yield: 28.2%).

[0597] LC-MS, M / Z(ESI):510.2[M+H] +

[0598] 1 H NMR(400MHz,cdcl3)δ7.41(q,J=7.9Hz,2H),6.77(s,1H),6.62(s,1H),5.56(s,2H),4.73(dt,J=20.2,6.4Hz,4H), 4.47(t,J=11.7Hz,4H),3.76–3.69(m,1H),3.54(s,2H),3.09(t,J=6.0Hz,2H),2.73(t,J=6.0Hz,2H),2.55(s,3H).

[0599] Example 15: Preparation of target compounds I-13 & I-13A

[0600] Synthesis of 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol (I-13)

[0601] Synthesis of 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (I-13A)

[0602] The synthetic routes of target compounds I-13 & I-13A are as follows:

[0603] Step 1: Synthesis of 2-(3,6-dichloropyridazin-4-yl)propan-2-ol

[0604] 3,6-Dichloro-1,2,4,5-tetrazine (500 mg, 3.31 mmol) and 2-methyl-3-butyn-2-ol (1.39 g, 16.6 mmol) were dissolved in toluene (5 mL) and stirred at 120°C for 12 hours. After the reaction was complete, the crude product was concentrated and purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 4:1, R f is 0.42) to give 2-(3,6-dichloropyridazin-4-yl)propan-2-ol (1.47 g, 42.8% yield).

[0605] LC-MS, M / Z(ESI):207.0[M+H] +

[0606] Step 2: Synthesis of 2-(6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol and 2-(6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol

[0607] Dissolve 2-(3,6-dichloropyridazin-4-yl)propan-2-ol (1.35 g, 6.52 mmol) and 5-methylisoxazole-3-carbohydrazide (920 mg, 6.52 mmol) in 1,4-dioxane (14 mL), add triethylamine hydrochloride (1.35 g, 9.78 mmol), and stir the reaction at 110 °C for 2 hours. After the reaction was complete, the crude product was filtered and concentrated to give a crude product, which was purified by preparative high performance liquid chromatography (chromatographic column: Waters Xbridge 150*25mm*5um; mobile phase: solvent A = water + 0.1% ammonia water, B = acetonitrile; gradient: 8%-38%, 10 min) to give a mixture of 2-(6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol and 2-(6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (465 mg, 24.2% yield).

[0608] LC-MS, M / Z(ESI):294.0[M+H] +

[0609] Step 3: Synthesis of 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol (I-13) and 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (I-13A)

[0610] A mixture of 2-(6-chloro-3-(5-methylisoxazol-3-yl)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol and 2-(6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (230 mg, 783 μmol) and (6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (190 mg, 861 μmol) were dissolved in N,N-dimethylformamide (3 mL). Cesium carbonate (510 mg, 1.57 mmol) was added and the reaction was stirred at 25°C for 12 hours. After the reaction was complete, the reaction solution was directly spin-dried to obtain a crude product, which was purified by high performance liquid chromatography (chromatographic column: Waters Xbridge 150*25mm*5um; mobile phase: solvent A = water + 0.1% ammonia water, B = acetonitrile; gradient: 5%-35%, 10 min) and concentrated to dryness to obtain a mixture.

[0611] The mixture was then separated and purified by supercritical fluid chromatography (column: DAICEL CHIRALCEL OJ (250 mm*30 mm, 10 μm; mobile phase A: [supercritical fluid carbon dioxide]; mobile phase B: isopropanol (0.05% diethylamine), gradient elution: supercritical fluid carbon dioxide containing ethanol (0.05% diethylamine), the ratio of which was from 5% to 40%; flow rate: 3 mL / min; detector: PDA); column temperature: 35° C.; column pressure: 100 bar) to obtain 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl) methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol (I-13) (172 mg, 45.6% yield, retention time 1.704 min) and 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (I-13A) (57.5 mg, 14.1% yield, retention time 1.942 min).

[0612] 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-2-ol (I-13)

[0613] LC-MS, M / Z(ESI):478.3[M+H] +

[0614] 1 H NMR (400MHz, CDCl3) δ8.20(s,1H),7.3-7.4(m,2H),6.83(s,1H),5.67(s,2H),4.75(t,J=6.4Hz,2H),4.71(t,J=6.4Hz,2H),4.47(br s,1H),3.69-3.75(m,1H),3.53(s,2H),3.09(t,2H,J=5.9Hz),2.72(t,2H,J=6.0Hz),2.58(s,3H),1.71(s,6H)

[0615] 2-(3-(5-methylisoxazol-3-yl)-6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)propan-2-ol (I-13A)

[0616] LC-MS, M / Z(ESI):478.3[M+H] +

[0617] 1 H NMR (400MHz, CDCl3) δ7.5-7.5(d,J=8Hz,1H),7.4-7.5(d,J=7.6Hz,1H),6.95(s,1H),6. 85(d,J=0.6Hz,1H),5.55(s,2H),4.7-4.8(m,4H),3.93(s,1H),3.7-3.8(m,1H),3.58(br s,2H),3.12-3.15(m,2H),2.76-2.79(m,2H),2.60(s,3H),1.82(s,6H)

[0618] Example 16: Preparation of target compound I-25

[0619] 4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one

[0620] The synthetic route of target compound I-25 is as follows:

[0621] Step 1: Synthesis of 1-((4-methoxyphenyl)methyl)-4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one

[0622] At room temperature, 6-chloro-3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazine (143 mg, 0.6 mmol), 4-(6-(hydroxymethyl)pyridazin-3-yl)-1-(4-methoxybenzyl)piperazin-2-one (200 mg, 0.6 mmol) and cesium carbonate (396.3 mg, 1.21 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50 ° C for 16 hours. LC-MS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, and the filtrate was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, followed by extraction with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (DCM / MeOH=15 / 1, v / v) to give 1-((4-methoxyphenyl)methyl)-4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one (140 mg, yield: 44%).

[0623] Step 2: Synthesis of 4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one

[0624] 1-((4-Methoxyphenyl)methyl)-4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one (140 mg, 0.26 mmol) was dissolved in toluene (6 mL) at room temperature, and trifluoromethanesulfonic acid (0.5 mL) was added. The reaction was then placed at 110° C. for 2 hours. LC-MS detected that the reaction was complete, and the reaction solution was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was separated by high performance liquid chromatography (column: Titank Prep C18 Bulk 10 μm, 30×40 mm, mobile phase: solvent A = acetonitrile, solvent B = water + 0.5% ammonia water, gradient: 34% acetonitrile) to obtain 4-(6-(((3-(5-methyl-1,2-oxazol-3-yl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)pyridazin-3-yl)piperazin-2-one (8.3 mg, yield: 7.6%).

[0625] LC-MS, M / Z(ESI):408.1[M+H] +

[0626] 1 H NMR (400MHz, DMSO) δ8.42(d,J=9.8Hz,1H),8.15(s,1H),7.73(d,J=9.4Hz,1H),7.31(d,J=9.4Hz,1H),7.24(d,J= 9.8Hz,1H),7.10(s,1H),5.58(s,2H),4.11(s,2H),3.85–3.80(m,2H),3.31(dd,J=4.6,1.6Hz,2H),2.59(s,3H).

[0627] Example 17: Preparation of target compound I-31

[0628] 2-(dideuterio((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0629] The synthetic route of target compound I-31 is as follows:

[0630] Step 1: Synthesis of 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0631] 2-Chloro-5,6,7,8-tetrahydropyrido[4,3-b]pyridine hydrochloride (5.0 g, 24.6 mmol), oxetane-3-one (1.95 g, 27.08 mmol), and triethylamine (2.48 g, 24.6 mmol) were dissolved in 50 mL of 1,2-dichloroethane and stirred at room temperature for 30 minutes. Then, sodium triacetylborohydride (10.3 g, 49.2 mmol) was added portionwise. The reaction mixture was allowed to react at room temperature for 16 hours. LC-MS indicated the reaction was complete. Water (100 mL) was added to the reaction solution, followed by extraction with dichloromethane (100 mL × 3). The organic phases were combined, washed with saturated brine (40 mL), and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (EtOAc / PE = 1:1) to give 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (5.3 g, yield: 95%).

[0632] LC-MS, M / Z(ESI):225.1[M+H] +

[0633] Step 2: Synthesis of 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0634] At room temperature, 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (5.3 g, 23.5 mmol) and Pd(dppf)Cl2 (1.72 g, 2.35 mmol) were dissolved in methanol / triethylamine (V / V): 8 / 1 (40 mL). The reaction solution was heated at 60°C under the protection of carbon monoxide for 16 hours. LC-MS showed that the reaction was complete. The reaction solution was concentrated to obtain a crude product, water (50 mL) was added to the crude product, and the mixture was extracted with dichloromethane (30 mL × 3). The organic phases were combined and washed with saturated brine (30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was separated by column chromatography (DCM / MeOH = 15:1) to give 2-chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (4.5 g, yield: 77%).

[0635] LC-MS, M / Z(ESI):249.1[M+H] +

[0636] Step 3: Synthesis of dideuterio(6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridin-2-yl)methanol

[0637] 2-Chloro-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (300 mg, 1.2 mmol) was dissolved in deuterated methanol (5 mL) under ice-cooling conditions, followed by the addition of sodium borodeuteride (150 mg, 3.6 mmol) and calcium chloride (124 mg, 1.2 mmol). The reaction mixture was allowed to react at room temperature for 4 hours, and LC-MS indicated completion. The reaction mixture was filtered to obtain a filtrate, which was then concentrated to afford the crude product, which was directly separated by column chromatography (DCM / MeOH = 10:1) to afford dideuterio(6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridin-2-yl)methanol (50 mg, yield: 18%).

[0638] LC-MS, M / Z(ESI):219.1[M+H] +

[0639] Step 4: Synthesis of 2-(dideuterio((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0640] At room temperature, 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methylisoxazole (52.6 mg, 2.24 mmol), (dideuterio(6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridin-2-yl)methanol (50 mg, 2.24 mmol) and cesium carbonate (140 mg, 4.48 mmol) were dissolved in acetonitrile (6 mL), and the reaction solution was reacted at 50°C for 16 hours. LC-MS showed that the reaction was complete. The reaction solution was filtered to obtain a filtrate, which was concentrated to obtain a crude product. Water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL×3). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was purified by high performance liquid chromatography (column: SunFire TM Prep C18 OBD TM5μm, 30X 150mm, mobile phase: solvent A = acetonitrile, solvent B = water + 0.5% formic acid, gradient: 25.2% acetonitrile) to separate and obtain 2-(dideuterio((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (12 mg, yield: 13%).

[0641] LC-MS, M / Z(ESI):422.3[M+H] +

[0642] 1 H NMR (400MHz, CDCl3) δ8.07(d,J=10.0Hz,1H),7.48(d,J=8.0Hz,1H),7.39(d,J=8.0Hz,1H),6.97(d,J=10.0Hz,1H),6.8 5(s,1H),4.77-4.69(m,4H),3.77–3.69(m,1H),3.53(s,2H),3.11(t,J=6.0Hz,2H),2.73(t,J=6.0Hz,2H),2.59(s,3H).

[0643] Example 18: Preparation of target compound I-33

[0644] 2-(((7-(Difluoromethyl)-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0645] The synthetic route of target compound I-33 is as follows:

[0646] Step 1: Synthesis of 3,6-dichloro-4-(difluoromethyl)pyridazine

[0647] 3,6-Dichloropyridazine (6.00 g, 40.3 mmol), difluoroacetic acid (4.06 g, 42.3 mmol, 2.66 mL) and sulfuric acid (5.14 g, 52.4 mmol, 2.98 mL) were dissolved in water (120 mL). Silver nitrate (821 mg, 4.83 mmol) was slowly added to the reaction solution, and the reaction solution was stirred at 60°C for 0.5 hour. Ammonium persulfate (18.4 g, 80.5 mmol, 17.5 mL) was added to the reaction solution at 60°C, and the reaction solution was stirred at 70°C for 1 hour. After the reaction was completed, the reaction solution was quenched with a saturated sodium bicarbonate solution (300 mL), and then extracted with ethyl acetate (80 mL × 3). The organic phase was washed with a saturated sodium chloride solution (100 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain 3,6-dichloro-4-(difluoromethyl)pyridazine. The crude product was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 3:1, R f The reaction mixture was stirred at 40 ℃ for 1 h (0.49) to give 3,6-dichloro-4-(difluoromethyl)pyridazine (2.80 g, 9.85 mmol, 24.5% yield, 70% purity).

[0648] LC-MS, M / Z(ESI):198.9[M+H] +

[0649] Step 2: Synthesis of 3-(6-chloro-7-(difluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methyl-1,2-oxazole

[0650] 5-Methylisothiazole-3-carboxylic acid hydrazide (600 mg, 4.25 mmol) and 3,6-dichloro-4-(difluoromethyl)pyridazine (1.06 g, 4.25 mmol) were dissolved in ethylene glycol monomethyl ether (4.00 mL), and then methanesulfonic acid (817 mg, 8.50 mmol, 608 μL) was added. The reaction solution was stirred at 100°C for 2 hours. After the reaction was completed, the reaction solution was quenched with saturated sodium bicarbonate solution (30 mL), then extracted with dichloromethane (20 mL × 3), dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: dichloromethane / methanol = 1:0 / 7:1, R f The product was then separated and purified by reverse-phase high performance liquid chromatography (chromatographic column: Phenomenex luna C18 150*25mm*10um; mobile phase: solvent A = water + 0.1% FA, B = acetonitrile; gradient: 30%-50%, 1 min) to obtain 3-(6-chloro-7-(difluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methyl-1,2-oxazole (600 mg, 1.60 mmol, 37.5% yield, 76% purity).

[0651] LC-MS, M / Z(ESI):285.9[M+H] +

[0652] Step 3: Synthesis of 2-(((7-(difluoromethyl)-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0653] 3-(6-Chloro-7-(difluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-methyl-1,2-oxazole (80.0 mg, 280 μmol) and (6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (74.0 mg, 336 μmol) were dissolved in N,N-dimethylformamide (2 mL), and cesium carbonate (137 mg, 420 μmol) was added. The reaction solution was stirred at 40°C for 12 hours. After completion of the reaction, the reaction solution was filtered and concentrated to obtain a crude product, which was then separated and purified by reverse-phase high performance liquid chromatography (chromatographic column: Phenomenex luna C18 150*25mm*10μm; mobile phase: solvent A=water+0.1% formic acid, B=acetonitrile; gradient: 2%-32%, 15 min) to obtain 2-(((7-(difluoromethyl)-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (14.87 mg, 27.7 μmol, 9.91% yield, 87.6% purity).

[0654] LC-MS, M / Z(ESI):470.2[M+H] +

[0655] 1H NMR(400MHz, DMSO-d6)δ8.79(s,1H),7.57(d,J=8.0Hz,1H),7.42(d,J=7.9Hz,1H),7.37-7.09(m,1H),7.22(t,J=53.5Hz,1H), 7.07(d,J=0.9Hz,1H),5.56(s,2H),4.62(t,J=6.4Hz,2H),4.52(t,J=6Hz,2H),3.63-3.65(m,1H),3.54-3.48(m,2H),2.93(br t,J=6.0Hz,2H),2.68-2.63(m,2H),2.59(s,3H)

[0656] Example 19: Preparation of target compound I-39

[0657] 5-methyl-3-(6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1,2,4-oxadiazole

[0658] The synthetic route of target compound I-39 is as follows:

[0659] Step 1: Synthesis of N'-(5-bromopyridin-2-yl)-5-methyl-1,2,4-oxadiazole-3-carbohydrazide

[0660] 5-Bromo-2-hydrazinopyridine (6.0 g, 31.91 mmol) and 5-methyl-1,2,4-oxadiazole-3-carboxylic acid (4.90 g, 38.3 mmol) were dissolved in N,N-dimethylformamide (90 mL). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (6.85 g, 35.7 mmol) and 1-hydroxybenzotriazole (4.31 g, 31.9 mmol) were added to the reaction solution in sequence. The reaction solution was stirred at 25 ° C for 2 hours. After the reaction was completed, the reaction solution was quenched with water (100 mL) at 0°C, and then extracted with ethyl acetate (50 mL×3). The organic phase was washed with saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to give a crude product, which was purified by reverse phase purification (0.1% formic acid) to give N'-(5-bromopyridin-2-yl)-5-methyl-1,2,4-oxadiazole-3-carbohydrazide (3.70 g, 12.4 mmol, 38.9% yield).

[0661] LC-MS, M / Z(ESI):297.9[M+H] +

[0662] 1 H NMR (400MHz, DMSO-d6) δ11.20(s,1H),8.96(s,1H),8.15(d,J=2.3Hz,1H),7.89-7.58(dd,J=2.4Hz,8.8Hz,1H),6.62(d,J=8.9Hz,1H),2.69(s,3H)

[0663] Step 2: Synthesis of 3-(6-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-methyl-1,2,4-oxadiazole

[0664] N'-(5-bromopyridin-2-yl)-5-methyl-1,2,4-oxadiazole-3-carbohydrazide (3.70 g, 12.4 mmol) and triphenylphosphine (6.51 g, 24.8 mmol) were dissolved in tetrahydrofuran (40 mL), and then triethylamine (5.02 g, 49.6 mmol, 6.91 mL) was added. 1,1,1,2,2,2-Hexachloroethane (5.88 g, 24.8 mmol, 2.81 mL) was added dropwise to the reaction solution at 0°C, and the reaction solution was stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was poured into water (100 mL) under a nitrogen atmosphere at 0°C and extracted with ethyl acetate (50 mL×3). The organic phase was washed with a saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to obtain a crude product, which was slurried in ethyl acetate (30 mL) at 25°C for 15 minutes to obtain 3-(6-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-methyl-1,2,4-oxadiazole (1.50 g, 5.36 mmol, 43.1% yield).

[0665] LC-MS, M / Z(ESI):279.9[M+H] +

[0666] Step 3: Synthesis of (3-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)boronic acid

[0667] 3-(6-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-methyl-1,2,4-oxadiazole (500 mg, 1.79 mmol) and bis-naphthalene alcohol borate (680 mg, 2.68 mmol) were dissolved in 1,4-dioxane (10 mL), and then 1,1-bis(diphenylphosphino)ferrocenepalladium chloride (131 mg, 178 μmol) and potassium acetate (526 mg, 5.36 mmol) were added. The reaction solution was stirred at 80 ° C for 12 hours. After the reaction was completed, the reaction solution was filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 0:1, R f The reaction mixture was stirred at 400 ℃ for 1 h (0.12) to give (3-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)boronic acid (400 mg, crude product).

[0668] LC-MS, M / Z(ESI):245.9[M+H] +

[0669] Step 4: Synthesis of 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1,2,4-oxadiazole

[0670] (3-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)boronic acid (100 mg, 408 μmol) and (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (135 mg, 612 μmol) were dissolved in dichloromethane (4 mL), and then 4A molecular sieves (500 mg), triethylamine (124 mg, 1.22 mmol, 170 μL) and anhydrous copper acetate (74.1 mg, 408 μmol) were added. The reaction solution was stirred at 35 ° C for 24 hours. After the reaction was completed, the reaction solution was filtered and concentrated to obtain a crude product, which was first purified by column chromatography (mobile phase: dichloromethane / methanol = 30:1 / 5:1, R f0.16) to obtain 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1,2,4-oxadiazole, which was then separated and purified by reverse-phase high performance liquid chromatography (column: Welch Xtimate C18 150*25mm*5um; mobile phase: solvent A = water + 0.1% formic acid, solvent B = acetonitrile; gradient: 1%-25%, 10min;) to give 5-methyl-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-1,2,4-oxadiazole (9.09 mg, 21.6 μmol, 5.29% yield).

[0671] LC-MS, M / Z(ESI):420.2[M+H] +

[0672] 1 H NMR (400MHz, DMSO-d6) δ8.68(d,J=1.8Hz,1H),8.02(d,J=9.9Hz,1H),7.61-7.49(m,2H),7.39(d,J=7.8Hz, 1H),5.22(s,2H),4.62(t,J=6.4Hz,2H),4.52(t,J=6.0Hz,2H),3.64(t,J=6.3Hz,1H),3.50(s,2H),2.95(br t,J=5.8Hz,2H),2.79(s,3H),2.65(t,J=5.6Hz,2H)

[0673] Example 20: Preparation of target compound I-40

[0674] 5-(Difluoromethyl)-3-(6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole

[0675] The synthetic route of target compound I-40 is as follows:

[0676] Step 1: Synthesis of ethyl 5-formylisoxazole-3-carboxylate

[0677] Ethyl 5-(hydroxymethyl)isoxazole-3-carboxylate (9.00 g, 52.6 mmol) was dissolved in dichloromethane (90 mL) at room temperature. The reaction mixture was cooled to 0°C before adding Dess-Martin periodinane (44.6 g, 105 mmol) portionwise. After addition, the reaction mixture was stirred at 25°C for 2 hours. After completion of the reaction, the reaction mixture was filtered and concentrated to obtain a crude product, which was then separated by column chromatography (petroleum ether:ethyl acetate 10:1 to 3:1) to afford ethyl 5-formylisoxazole-3-carboxylate (8.10 g, 91.0% yield).

[0678] Step 2: Synthesis of ethyl 5-(difluoromethyl)isoxazole-3-carboxylate

[0679] Ethyl 5-formylisoxazole-3-carboxylate (8.00 g, 47.3 mmol) was dissolved in dichloromethane (80 mL) at room temperature. After cooling to 0°C, diethylaminosulfur trifluoride (15.3 g, 94.6 mmol) was slowly added dropwise. The reaction solution was stirred at 25°C for 2 hours. After completion of the reaction, the reaction solution was slowly poured into saturated sodium bicarbonate solution to quench the reaction. Dichloromethane (50 mL x 3) was then added for extraction. The organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, and filtered and concentrated to yield ethyl 5-(difluoromethyl)isoxazole-3-carboxylate (8.00 g, crude product).

[0680] Step 3: Synthesis of 5-(difluoromethyl)isoxazole-3-carbohydrazide

[0681] Ethyl 5-(difluoromethyl)isoxazole-3-carboxylate (4.00 g, 20.9 mmol) was dissolved in ethanol (40 mL) at room temperature, and hydrazine hydrate (1.85 g, 31.4 mmol) was slowly added dropwise. The reaction solution was stirred at 60°C for 2 hours. After the reaction, the ethanol was concentrated to dryness to obtain 5-(difluoromethyl)isoxazole-3-carbohydrazide (3.60 g, crude product).

[0682] LC-MS, M / Z(ESI):178.1[M+H] +

[0683] Step 4: Synthesis of 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(difluoromethyl)isoxazole

[0684] 5-(Difluoromethyl)isoxazole-3-carbohydrazide (1.00 g, 5.65 mmol) and 3,6-dichloropyridazine (841 mg, 5.65 mmol) were dissolved in toluene (10 mL) at room temperature. p-Toluenesulfonic acid (194 mg, 1.13 mmol) was added, and the reaction mixture was stirred at 110°C for 2 hours. After completion of the reaction, the reaction mixture was concentrated to dryness to obtain the crude product, which was then purified by reverse phase chromatography (0.1% formic acid) to afford 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(difluoromethyl)isoxazole (150 mg, 9.78% yield).

[0685] LC-MS, M / Z(ESI):272.0[M+H] +

[0686] 1 H NMR (400MHz, CDCl3) δ8.25 (d, J = 9.6Hz, 1H), 7.49 (s, 1H), 7.31 (d, J = 9.6Hz, 1H), 6.75-7.05 (t, J = 53.2Hz, 1H).

[0687] Step 5: Synthesis of 5-(difluoromethyl)-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole

[0688] At room temperature, 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(difluoromethyl)isoxazole (90.0 mg, 331 μmol) and (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (80.3 mg, 364 mmol) were dissolved in tetrahydrofuran (2 mL). The reaction solution was cooled to 0°C and added in batches under nitrogen protection. Sodium hydride (26.5 mg, 665 μmol, 60% purity) was added, and the reaction solution was stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was poured into a 0.5 M dilute hydrochloric acid solution (2 mL) for quenching, and ethyl acetate (5 mL × 3) was added for extraction. The organic phase was washed with a saturated sodium chloride solution (10 mL) and dried over anhydrous sodium sulfate, and then filtered and concentrated to obtain a crude product. The crude product was separated and purified by reverse phase high performance liquid chromatography (column: Waters The product was purified by Xbridge 150*25mm*5um; mobile phase: solvent A = water + 0.1% ammonia water, solvent B = acetonitrile; gradient: 8%-38% B, 10 min) to give 5-(difluoromethyl)-3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)isoxazole (26.5 mg, 17.1% yield).

[0689] LC-MS, M / Z(ESI):456.1[M+H] +

[0690] 1 H NMR (400MHz, DMSO-d6) δ8.48(d,J=10Hz,1H),7.79(t,J=1.6Hz,1H),7.54(d,J=7.6Hz,1H),7.52(t,J=52.4Hz,1H),7.42(d,J=7.6Hz,1H),7.34(d,J=10Hz 1H), 5.49 (s, 2H), 4.61 (t, J = 6.4Hz, 2H), 4.52 (t, J = 6.0Hz, 2H), 3.63 (quin, J = 6.0Hz, 1H), 3.50 (s, 2H), 2.92 (t, J = 5.6Hz, 2H), 2.64 (t, J = 6.0Hz, 2H).

[0691] Example 21: Preparation of target compound I-41

[0692] 3-(6-((6-(oxetan-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole

[0693] The synthetic route of the target compound I-41 is as follows:

[0694] Step 1: Ethyl 5-(trifluoromethyl)isoxazole-3-carboxylate

[0695] Ethyl 2-chloro-2-(oximino)acetate (10.0 g, 65.9 mmol) and 2-bromo-3,3,3-trifluoropropene-1-ene (34.6 g, 197 mmol) were dissolved in tetrahydrofuran (100 mL). Potassium carbonate (18.2 g, 131 mmol) was then added, and the reaction mixture was stirred at 25°C for 12 hours. After completion of the reaction, ethyl 5-(trifluoromethyl)isoxazole-3-carboxylate (14.5 g, crude product) was directly filtered and used in the next step.

[0696] Step 2: 5-(Trifluoromethyl)isoxazole-3-carbohydrazide

[0697] Ethyl 5-(trifluoromethyl)isoxazole-3-carboxylate (10 g, 47.82 mmol) was dissolved in ethanol (120 mL). Hydrazine hydrate (4.22 g, 71.7 mmol, 4.09 mL, 85% content) was then added at 0°C. The reaction solution was stirred at 25°C for 2 hours. After completion of the reaction, the crude product was directly filtered and concentrated to obtain a crude product, which was then separated and purified by column chromatography (mobile phase: dichloromethane:methanol (v / v) = 10:1) to obtain 5-(trifluoromethyl)isoxazole-3-carbohydrazide (3.80 g).

[0698] LC-MS, M / Z(ESI):195.9[M+H] +

[0699] Step 3: 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole

[0700] 3,6-Dichloropyridazine (800 mg, 5.37 mmol) and 5-(trifluoromethyl)isoxazole-3-carbohydrazide (1.47 g, 7.52 mmol) were dissolved in toluene (20 mL). p-Toluenesulfonic acid (277 mg, 1.61 mmol) was then added, and the reaction mixture was stirred at 110°C for 2 hours. After completion of the reaction, the mixture was concentrated to obtain a crude product, which was then isolated and purified by column chromatography (mobile phase: petroleum ether:ethyl acetate (v / v) = 5:1 to 0:1) to afford 3-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole (250 mg, 16.1% yield).

[0701] LC-MS, M / Z(ESI):289.9[M+H] +

[0702] Step 4: 3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole

[0703] 3-(6-Chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole (120 mg, 414 μmol) and (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (110 mg, 497 μmol) were dissolved in tetrahydrofuran (2 mL), and sodium hydride (33.1 mg, 828 μmol, 60% content) was added at 0°C, and the reaction solution was stirred at 25°C for 2 hours. After completion of the reaction, the reaction mixture was cooled to 0°C and the reaction solution was slowly added dropwise to a saturated ammonium chloride solution (10 mL) for quenching. The mixture was then extracted with ethyl acetate (10 mL × 3). The organic phase was washed with a saturated sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to obtain a crude product, which was separated and purified by reverse-phase high performance liquid chromatography (chromatographic column: Waters Xbridge 150*25 mm*5 um; mobile phase: solvent A = water + 0.1% NH4HCO3, B = acetonitrile; gradient: 35%-65%, 9 min) to obtain 3-(6-((6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-5-(trifluoromethyl)isoxazole (50.0 mg, yield 25.2%).

[0704] LC-MS, M / Z(ESI):474.2[M+H] +

[0705] 1 H NMR (400MHz, DMSO-d6) δ8.50(d,J=9.6Hz,1H),8.20(s,1H),7.54(d,J=7.88Hz,1H),7.42(d,J=7.88Hz,1H),7.36(d,J=9.88Hz,1H),5.5 2(s,2H),4.61(t,J=6.4Hz,2H),4.51(t,J=6.08Hz,2H),3.59-3.65(m,1H),3.49(s,2H),2.91(t,J=5.88Hz,2H),2.63(t,J=5.94Hz,2H).

[0706] Example 22: Preparation of target compound I-42

[0707] 2-(((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0708] The synthetic route of target compound I-42 is as follows:

[0709] Step 1: Synthesis of 6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine

[0710] 5-Chloro-2-hydrazinopyridine (1.2 g, 8.3 mmol) and 5-methylisoxazole-3-carbaldehyde (1.02 g, 9.2 mmol) were dissolved in ethanol (20 mL) at room temperature. The reaction mixture was then reacted at 90°C for 2 hours. LC-MS showed that the reaction was complete. The reaction solution was concentrated to obtain a crude product. DCM (20 mL) was added to the crude product, and then iodophenyl diacetic acid (2.97 g, 9.2 mmol) was added to the reaction system. The reaction was allowed to react overnight at room temperature. LC-MS showed that the reaction was complete. The mixture was extracted with dichloromethane (20 mL × 3), and the organic phases were combined and washed with saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried. The crude product was purified by column chromatography (PE / EtOAc (v / v) = 1 / 1) to give 6-chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine (1 g, yield: 50.6%).

[0711] LC-MS, M / Z(ESI):235.1[M+H] +

[0712] Step 2: Synthesis of 3-(5-methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)[1,2,4]triazolo[4,3-a]pyridine

[0713] 6-Chloro-3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridine (1.0 g, 4.2 mmol) was dissolved in 1,4-dioxane (20 mL), and then Pd(dppf)Cl2 (622 mg, 0.8 mmol), diboronic acid pinacol ester (1.3 g, 5.1 mmol) and potassium acetate (834 mg, 8.5 mmol) were added in sequence. The reaction solution was heated to reflux at 90 ° C under nitrogen protection for 16 hours. LC-MS showed that the reaction was complete. The solvent was evaporated to dryness, the organic phase was concentrated, and the residue was purified by silica chromatography (DCM / MeOH (V / V) = 15 / 1) to give 3-(5-methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)[1,2,4]triazolo[4,3-a]pyridine (1.3 g crude product).

[0714] LC-MS, M / Z(ESI):327.2[M+H] +

[0715] Step 3: Synthesis of (3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-yl)boranediol

[0716] 3-(5-Methylisoxazol-3-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)[1,2,4]triazolo[4,3-a]pyridine (1.3 g) was dissolved in tetrahydrofuran (20 mL) at room temperature, followed by the addition of 1N sodium hydroxide solution (10 mL). The reaction mixture was allowed to react for 1 hour. LC-MS indicated the reaction was complete. The product was used directly in the next reaction without further treatment.

[0717] LC-MS, M / Z(ESI):245.1[M+H] +

[0718] Step 4: Synthesis of 3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-ol

[0719] To the reaction solution of crude (3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-yl)boranediol was added (2 mL) of H2O2 at room temperature, followed by stirring at room temperature for 30 min. LC-MS showed that the reaction was complete. Dichloromethane (20 mL) and water (10 mL) were added to the reaction solution, and extraction was performed to obtain an aqueous phase. The aqueous phase was adjusted to pH 3-4 with 3N HCl, and then extracted with dichloromethane (30 mL). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried to give a crude product. The crude product was purified by column chromatography (DCM / MeOH (V / V) = 15 / 1) to give 3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-ol (250 mg).

[0720] LC-MS, M / Z(ESI):217.1[M+H] +

[0721] Step 5: Synthesis of 2-(((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0722] At room temperature, 3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-ol (250 mg, 1.15 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (254 mg, 1.15 mmol), and triphenylphosphine (363 mg, 1.38 mmol) were dissolved in toluene (10 mL) and stirred under nitrogen for 30 min. Then, diisopropyl azodicarboxylate (DIAD) (350 mg, 1.73 mmol) was slowly added dropwise. The reaction was allowed to react at room temperature for 5 hours. LC-MS showed that the reaction was complete. The reaction solution was concentrated to give a crude product, water (10 mL) was added to the crude product, and then extracted with dichloromethane (10 mL × 3), the organic phases were combined, washed with saturated brine (10 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and spin-dried. The crude product was purified by high performance liquid chromatography (column: Titank Prep C18 Bulk 10 μm, 30X 40 mm, mobile phase: solvent A = water + 0.5% ammonia water, solvent B = acetonitrile, 52% acetonitrile) to give 2-(((3-(5-methylisoxazol-3-yl)[1,2,4]triazolo[4,3-a]pyridin-6-yl)oxy)methyl)-6-(oxetane-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (8.0 mg, yield: 1.6%).

[0723] LC-MS, M / Z(ESI+):419.2[M+H] +

[0724] 1 H NMR (400MHz, CDCl3) δ8.83(s,1H),7.79(d,J=10.0Hz,1H),7.42(d,J=8.0Hz,1H),7.37(d,J=8.0Hz,1H),7.29(dd,J=10.0,1.6Hz,1H),6.85( s,1H),5.21(s,2H),4.74(dt,J=15.6,6.0Hz,4H),3.77–3.71(m,1H),3.55(s,2H),3.14(t,J=6.0Hz,2H),2.75(t,J=6.0Hz,2H),2.57(s,3H).

[0725] Example 23: Preparation of target compound I-43

[0726] 2-(2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,3-diol

[0727] The route of target compound I-43 is as follows:

[0728] Step 1: Synthesis of 3,6-dichloro-4-(trimethylsilyl)pyridazine

[0729] 3,6-Dichloropyridazine (12.0 g, 80.6 mmol) and trimethylsilyl chloride (10.5 g, 96.6 mmol, 12.3 mL) were dissolved in tetrahydrofuran (120 mL). After the temperature was lowered to -70°C, a 1.0 M solution of 2,2,6,6-tetramethylpiperidinium chloride and lithium magnesium chloride in n-hexane (177.21 mL) was slowly added dropwise to the reaction solution. The reaction solution was stirred at -70°C for 2 hours. After the reaction was completed, the reaction solution was quenched with saturated ammonium chloride solution (1 L) and then extracted with ethyl acetate (300 mL × 3). The organic phase was washed with saturated sodium chloride solution (600 mL) and dried over anhydrous sodium sulfate. After filtration and concentration, 3,6-dichloro-4-(trimethylsilyl)pyridazine was obtained. The crude product was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 30:1 / 10:1, R f is 0.36) to give 3,6-dichloro-4-(trimethylsilyl)pyridazine (15.0 g, 67.82 mmol, 84.2% yield).

[0730] LC-MS, M / Z(ESI):220.9[M+H] +

[0731] Step 2: Synthesis of 3-chloro-6-hydrazino-4-(trimethylsilyl)pyridazine

[0732] 3,6-Dichloro-4-(trimethylsilyl)pyridazine (8.00 g, 36.1 mmol) was dissolved in tetrahydrofuran (80 mL), followed by the addition of hydrazine hydrate (6.34 g, 126 mmol, 6.14 mL). The reaction mixture was stirred at 65°C for 2 hours. After completion of the reaction, the reaction mixture was concentrated at low temperature to obtain a crude product, which was then purified by reverse-phase HPLC (UniSil 10-120C18 70 × 250 mm column; mobile phase: solvent A = water + 0.1% formic acid, solvent B = acetonitrile; gradient: 5% to 35% over 20 min) to afford 3-chloro-6-hydrazino-4-(trimethylsilyl)pyridazine (600 mg, 2.77 mmol, 7.65% yield).

[0733] LC-MS, M / Z(ESI):217.7[M+H] +

[0734] Step 3: Synthesis of N'-(6-chloro-5-(trimethylsilyl)pyridazin-3-yl)-4-fluorobenzohydrazide

[0735] 3-Chloro-6-hydrazino-4-(trimethylsilyl)pyridazine (300 mg, 1.38 mmol) and triethylamine (210 mg, 2.08 mmol) were dissolved in tetrahydrofuran (6 mL), and then 4-fluorobenzoyl chloride (264 mg, 1.66 mmol) was added at 0°C. The reaction solution was stirred at 0°C for 1 hour. After the reaction was completed, the reaction solution was poured into water (50 mL) at 0°C, and then extracted with ethyl acetate (10 mL×3). The organic phase was washed with saturated sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to obtain a crude brown solid. The crude product was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 5:1 / 1:1, R f The reaction mixture was stirred at 40 ℃ for 10 min (0.31) to give N'-(6-chloro-5-(trimethylsilyl)pyridazin-3-yl)-4-fluorobenzohydrazide (710 mg, 2.10 mmol, 75.6% yield).

[0736] LC-MS, M / Z(ESI):339.0[M+H] +

[0737] Step 4: Synthesis of 6-chloro-3-(4-fluorophenyl)-7-(trimethylsilyl)-[1,2,4]triazolo[4,3-b]pyridazine

[0738] N'-(6-Chloro-5-(trimethylsilyl)pyridazin-3-yl)-4-fluorobenzohydrazide (660 mg, 1.95 mmol) and 1,2-dibromo-1,1,2,2-tetrachloro-ethane (1.27 g, 3.90 mmol) were dissolved in acetonitrile (12 mL), and then triphenylphosphine (1.28 g, 4.87 mmol) was added at 0°C. The reaction solution was stirred at 0°C for 15 minutes. Triethylamine (1.18 g, 11.69 mmol, 1.63 mL) was added dropwise to the reaction solution at 0°C, and the reaction solution was stirred at 0°C for 3 hours. After the reaction was completed, the reaction solution was poured into water (50 mL) under a nitrogen atmosphere at 0°C and extracted with ethyl acetate (20 mL × 3). The organic phase was washed with a saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 3:1, R f 0.38) to give 6-chloro-3-(4-fluorophenyl)-7-(trimethylsilyl)-[1,2,4]triazolo[4,3-b]pyridazine (570 mg, 1.78 mmol, 91.2% yield).

[0739] LC-MS, M / Z(ESI):321.0[M+H] +

[0740] Step 5: Synthesis of 7-bromo-6-chloro-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine

[0741] 6-Chloro-3-(4-fluorophenyl)-7-(trimethylsilyl)-[1,2,4]triazolo[4,3-b]pyridazine (550 mg, 1.71 mmol) and 1,2-dibromo-1,1,2,2-tetrachloro-ethane (2.23 g, 8.57 mmol) were dissolved in tetrahydrofuran (11 mL), and then tetrabutylammonium difluorotriphenylstannate (1.19 g, 1.89 mmol) was added. The reaction solution was stirred at 25°C for 12 hours. After the reaction was completed, the reaction solution was poured into dichloromethane (40 mL) for dilution, then filtered, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 10:1 / 2:1, R f is 0.33) to give 7-bromo-6-chloro-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine (430 mg, 1.31 mmol, 76.5% yield).

[0742] LC-MS, M / Z(ESI):328.9[M+H] +

[0743] 1 H NMR(400MHz,DMSO-d6)δ9.16(s,1H),8.42-8.24(m,2H),7.53-7.47(m,2H)

[0744] Step 6: Synthesis of tert-butyl 2-(((7-bromo-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate

[0745] 7-Bromo-6-chloro-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine (210 mg, 641 μmol) and tert-butyl 2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (203 mg, 769 μmol) were dissolved in N,N-dimethylformamide (6 mL), and cesium carbonate (418 mg, 1.28 mmol) was added. The reaction solution was stirred at 40°C for 3 hours. After the reaction was completed, the reaction solution was poured into water (50 mL) at 0°C and extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated sodium chloride solution (50 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to obtain the crude product. The crude product was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 3:1 / 0:1, R f The reaction mixture was stirred at 4 ℃ for 1 hr (0.31) to give tert-butyl 2-(((7-bromo-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (250 mg, 397.46 μmol, 61.99% yield).

[0746] LC-MS, M / Z(ESI):557.0[M+H] +

[0747] Step 7: Synthesis of tert-butyl 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate

[0748] Tert-butyl 2-(((7-bromo-3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (340 mg, 612 μmol) and cesium carbonate (399 mg, 1.22 mmol) were dissolved in 1,4-dioxane (7 mL), and tris(dibenzylideneacetone)dipalladium (56.1 mg, 61.2 μmol), 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl (52.0 mg, 122 μmol) and methanol (196 mg, 6.12 mmol, 248 μL) were added, and the reaction solution was stirred at 70°C for 12 hours. After the reaction was completed, the reaction solution was poured into water (40 mL) at 0°C, and then extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated sodium chloride solution (20 mL) and dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by column chromatography (mobile phase: petroleum ether / ethyl acetate = 5:1 / 1:1, R f The reaction mixture was stirred at 4 ℃ for 1 hr (0.28) to give tert-butyl 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (116 mg, 229 μmol, 37.4% yield).

[0749] LC-MS, M / Z(ESI):507.1[M+H] +

[0750] Step 8: Synthesis of 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine

[0751] Tert-butyl 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate (120 mg, 237 μmol) was dissolved in 1,4-dioxane (3 mL), and then a 1,4-dioxane HCl solution (2 M, 3 mL) was added. The reaction solution was stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was concentrated to give a crude product of 2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (120 mg), which was used directly in the next step.

[0752] LC-MS, M / Z(ESI):407.1[M+H] +

[0753] Step 9: Synthesis of 6-(2,2-dimethyl-1,3-dioxane-5-yl)-2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine

[0754] 2-(((3-(4-Fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (120 mg, 270.96 μmol) and 2,2-dimethyl-1,3-dioxan-5-one (52.9 mg, 406 μmol) were dissolved in tetrahydrofuran (2.4 mL), and sodium acetate (66.7 mg, 813 μmol) was added. After the reaction solution was stirred at 25°C for 0.5 hour, sodium acetate borohydride (115 mg, 542 μmol) was added to the reaction solution, and the reaction solution was stirred at 25°C for 12 hours. After completion of the reaction, the reaction solution was poured into water (10 mL) at 0°C and extracted with ethyl acetate (5 mL × 3). The organic phase was washed with saturated sodium chloride solution (10 mL) and dried over anhydrous sodium sulfate, then filtered and concentrated to give 6-(2,2-dimethyl-1,3-dioxan-5-yl)-2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (130 mg, crude product). This was used directly in the next step.

[0755] LC-MS, M / Z(ESI):521.2[M+H] +

[0756] Step 10: Synthesis of 2-(2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,3-diol

[0757] 6-(2,2-Dimethyl-1,3-dioxan-5-yl)-2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-5,6,7,8-tetrahydro-1,6-naphthyridine (130 mg, 249.73 μmol) was dissolved in 1,4-dioxane (1.3 mL), and then a 1,4-dioxane HCl solution (2 M, 1.30 mL) was added, and the reaction solution was stirred at 25 ° C for 1 hour. After completion of the reaction, the reaction solution was concentrated to obtain a crude product, which was then separated and purified by reverse-phase high performance liquid chromatography (column: Welch Xtimate C18 150*25mm*5μm; mobile phase: solvent A = water + 0.1% formic acid, solvent B = acetonitrile; gradient: 1%-30%, 10 min) to obtain 2-(2-(((3-(4-fluorophenyl)-7-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)propane-1,3-diol (45.92 mg, 94.3 μmol, 37.7% yield).

[0758] LC-MS, M / Z(ESI):481.2[M+H] +

[0759] 1 H NMR (400MHz, DMSO-d6) δ8.37-8.29(m,2H),7.70(s,1H),7.53(d,J=7.8Hz,1H),7.41(t,J=8.9Hz,2H),7.32(d,J=7.9Hz,1H),5.47 (s,2H),4.56-4.17(m,2H),3.98(s,3H),3.89(s,2H),3.64-3.48(m,4H),3.05-2.95(m,2H),2.92-2.81(m,2H),2.76-2.69(m,1H)

[0760] Example 24: Preparation of target compound I-44

[0761] 2-(((3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0762] The synthetic route of target compound I-44 is as follows:

[0763] Step 1: Synthesis of methyl 4-fluoro-5-methylisoxazole-3-carboxylate

[0764] Methyl 5-methylisoxazole-3-carboxylate (10 g, 70.9 mmol) and a selective fluorination reagent (30.1 g, 85.1 mmol) were added sequentially to 80 mL of sulfolane, heated at 120 ° C. for 16 h, and the reaction system was cooled to room temperature. 200 mL of water was added and extracted twice with 50 mL of ethyl acetate. The combined organic phases were dried and concentrated, and the crude product was purified by silica gel column (PE / EA = 3 / 1) to give methyl 4-fluoro-5-methylisoxazole-3-carboxylate (500 mg, yield 4.5%).

[0765] Step 2: Synthesis of 4-fluoro-5-methylisoxazole-3-carboxylic acid hydrazide

[0766] Methyl 4-fluoro-5-methylisoxazole-3-carboxylate (500 mg, 3.14 mmol) and hydrazine hydrate (800 mg, 15.7 mmol) were added sequentially to 5 mL of ethanol and reacted at 60 ° C for 2 hours. The reaction system was cooled to room temperature and concentrated. The crude product was purified by silica gel column (DCM / MeOH = 30 / 1) to give 4-fluoro-5-methylisoxazole-3-carboxylic acid hydrazide (400 mg, yield 80%).

[0767] LC-MS, M / Z(ESI):160.1[M+H] +

[0768] Step 3: Synthesis of 6-chloro-3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine

[0769] 3,6-Dichloropyridazine (374 mg, 2.51 mmol) and 4-fluoro-5-methylisoxazole-3-carboxylic acid hydrazide (400 mg, 2.51 mmol) were added sequentially to 4 mL of n-butanol and heated under reflux for 4 hours under nitrogen protection. The reaction system was cooled to room temperature and concentrated. The crude product was purified by silica gel column (PE / EA=3 / 1) to give 6-chloro-3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]triazine (350 mg, yield 54.9%).

[0770] LC-MS, M / Z(ESI):254.1[M+H] +

[0771] Step 4: Synthesis of 2-(((3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0772] 6-Chloro-3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine (350 mg, 1.37 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (360 mg, 1.65 mmol), and potassium carbonate (378 mg, 2.74 mmol) were added to anhydrous acetonitrile (8 mL) in sequence, and the reaction system was reacted at 50°C for 2 hours, cooled to room temperature, and then reacted. Water (20 mL) was added to the mixture and the mixture was extracted twice with ethyl acetate (20 mL) and concentrated. The crude product was first quickly purified by silica gel column to obtain the crude product, and then separated and purified by Pre-HPLC and dried to give 2-(((3-(4-fluoro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (200 mg, yield 34.1%).

[0773] LC-MS, M / Z(ESI):438.2[M+H] +

[0774] 1 H NMR(400MHz,cdcl3)δ8.08(d,J=9.8Hz,1H),7.39(dd,J=17.8,7.8Hz,2H),6.99(d,J=9.8Hz,1H),5.48(s,2H),4.71(dt,J= 18.6, 6.4Hz, 4H), 3.71 (p, J = 6.4Hz, 1H), 3.52 (s, 2H), 3.08 (t, J = 5.8Hz, 2H), 2.71 (t, J = 6.0Hz, 2H), 2.56 (d, J = 2.2Hz, 3H).

[0775] Example 25: Preparation of target compound I-45

[0776] 2-(((3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0777] The synthetic route of target compound I-45 is as follows:

[0778] Step 1: Synthesis of methyl 4-chloro-5-methylisoxazole-3-carboxylate

[0779] Methyl 5-methylisoxazole-3-carboxylate (5 g, 35.4 mmol) and N-chlorosuccinimide (9.2 g, 70.8 mmol) were added to 60 mL of glacial acetic acid in sequence, heated at 120 ° C for 16 h, and the reaction system was cooled to room temperature. 200 mL of water was added and extracted twice with 50 mL of ethyl acetate. The combined organic phases were adjusted to pH 7-8 with saturated sodium bicarbonate aqueous solution and separated again, dried and concentrated to obtain 6.0 g of crude product, which was directly used in the next step.

[0780] Step 2: Synthesis of 4-chloro-5-methylisoxazole-3-carbohydrazide

[0781] Methyl 4-chloro-5-methylisoxazole-3-carboxylate (2.0 g, 11.4 mmol) and hydrazine hydrate (1.2 g, 22.8 mmol) were added sequentially to 20 mL of ethanol and reacted at 60 ° C for 2 hours. The reaction system was cooled to room temperature and concentrated, and the crude product was purified by silica gel column (DCM / MeOH = 30 / 1) to give 4-chloro-5-methylisoxazole-3-carboxylic acid hydrazide (1.4 g, yield 70%).

[0782] LC-MS, M / Z(ESI):176.1[M+H] +

[0783] Step 3: Synthesis of 6-chloro-3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine

[0784] 3,6-Dichloropyridazine (760 mg, 5.11 mmol) and 4-chloro-5-methylisoxazole-3-carboxylic acid hydrazide (900 mg, 5.11 mmol) were added to 5 mL of n-butanol in sequence, and the mixture was heated under reflux for 4 hours under nitrogen protection. The reaction system was cooled to room temperature and filtered. The solid was washed with petroleum ether and dried to obtain 6-chloro-3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine (1.0 g), which was used directly in the next step.

[0785] Step 4: Synthesis of 2-(((3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine

[0786] 6-Chloro-3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazine (500 mg, 1.85 mmol), (6-(oxetane-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)methanol (407 mg, 1.85 mmol) and potassium carbonate (510 mg, 3.7 mmol) were added to anhydrous acetonitrile (10 mL) in sequence, and the reaction system was reacted at 50°C for 2 hours, cooled to room temperature and then reacted. Water (20 mL) was added to the mixture and the mixture was extracted twice with ethyl acetate (20 mL) and concentrated. The crude product was first quickly purified by silica gel column to obtain the crude product, and then separated and purified by Pre-HPLC and dried to give 2-(((3-(4-chloro-5-methylisoxazol-3-yl)[1,2,4]triazolo[3,4-f][1,2]diazin-6-yl)oxy)methyl)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-b]pyridine (71.2 mg, yield 8.4%).

[0787] LC-MS, M / Z(ESI):454.1[M+H] +

[0788] 1 H NMR(400MHz,cdcl3)δ8.09(d,J=9.8Hz,1H),7.44–7.31(m,2H),6.98(d,J=9.8Hz,1H),5.46(s,2H),4.71(dt,J= 17.8, 6.2Hz, 4H), 3.71 (p, J = 6.4Hz, 1H), 3.52 (s, 2H), 3.07 (t, J = 5.8Hz, 2H), 2.71 (t, J = 6.0Hz, 2H), 2.56 (s, 3H).

[0789] Example 26: The following compounds were prepared by referring to the preparation methods of the above compounds.

[0790] In the test examples of the present invention, the preparation method of the control compound I refers to patent WO2021121294A1, and the structure is shown below:

[0791] Biological testing

[0792] The following test method may be used.

[0793] Test Example 1: Inverse agonist activity of compounds on α5-GABAA receptors

[0794] This assay utilizes a HEK-293 cell line transiently expressing GABAA (α5β3γ2) receptors. Test compounds were prepared on the day of assay and re-dissolved in extracellular solution. The extracellular solution consisted of: 140 mM NaCl, 5 mM CsCl, 2 mM CaCl2·2H2O, 1 mM MgCl2·6H2O, 5 mM HEPES, 10 mM D-Glucose, and pH adjusted to 7.4 with NaOH. The intracellular solution consisted of: 130 mM CsCl, 0.1 mM CaCl2·2H2O, 2 mM MgCl2·6H2O, 1.1 mM EGTA, 5 mM Na2-ATP, 10 mM HEPES, and pH adjusted to 7.2 with CsOH. Test compounds were dissolved in dimethyl sulfoxide (DMSO) and re-dissolved in extracellular solution on the day of assay to a final concentration of 100 nM.

[0795] First, a recording electrode is drawn from a capillary glass tube using a microelectrode puller. The electrode, filled with intracellular fluid, is then placed in a microelectrode holder. Under an inverted microscope, the microelectrode manipulator is used to immerse the electrode in the extracellular fluid and record the electrode resistance (Rpip). The electrode is then slowly brought into contact with the cell surface, and negative pressure is applied to create a GΩ high-resistance seal. Fast capacitance compensation is then performed, and negative pressure is continued to rupture the cell membrane, establishing whole-cell recording mode. Finally, slow capacitance compensation is performed, and experimental parameters such as series resistance (Rs) are recorded. No leakage compensation is applied. Once a whole-cell seal is established, the cell membrane voltage is clamped at -70 mV, and GABA receptor currents are recorded in gap-free mode.

[0796] When detecting the inverse agonist effect of the test substance, the peak current after the EC50 concentration of GABA, the mixture of EC50 concentration of GABA and the test substance detection concentration, and the saturation concentration of GABA are sequentially administered to the cell surface. After each switching of the working solution, the solution is eluted with extracellular fluid, and the next working solution is switched after the current stabilizes. The experimental data are collected by the EPC 10 amplifier (HEKA) and stored in the PatchMaster (HEKA) software. At least 2 cells are used for each concentration to repeat the test 2 times independently. All electrophysiological tests are carried out at room temperature. During the test, the peak current stimulated by GABA before administration (IGABA) and the peak current after the test substance detection concentration (I Cmpd ), the peak current after the mixture of the test substance and GABA acts (IGABA+Cmpd ) and the peak current evoked by saturating concentration of GABA (I GABA saturated ) . The antagonistic effect of the test substance was calculated during analysis, i.e. (1-(I Cmpd / I GABA )*100%), reverse agonism, i.e. (1-(I GABA+Cmpd ) / (I GABA )*100%).

[0797] Table 1. Inverse agonist activity data of compounds (100 nM) at α5-GABAA receptor

[0798] The experimental results show that the compound of the present invention has strong inverse agonist activity on α5-GABAA receptor.

[0799] Test Example 2: Pharmacokinetics test in rats

[0800] For a pharmacokinetic study in rats, three male Sprague-Dawley rats (180-240 g) were fasted overnight and administered 10 mg / kg orally by gavage. Blood was collected before dosing and at 15, 30 minutes, and 1, 2, 4, 6, 8, and 24 hours after dosing. Blood samples were centrifuged at 8000 rpm for 6 minutes at 4°C, and plasma was collected and stored at -20°C. Plasma was collected at each time point and mixed with 3-5 times the volume of acetonitrile containing the internal standard. The mixture was vortexed for 1 minute and centrifuged at 13000 rpm for 10 minutes at 4°C. The supernatant was then mixed with 3 times the volume of water, and an appropriate amount of the mixture was analyzed by LC-MS / MS. Key pharmacokinetic parameters were analyzed using a non-compartmental model using WinNonlin 7.0 software.

[0801] Table 2. Pharmacokinetic test results in rats

[0802] The experimental results show that the compound of the present invention has good pharmacokinetic properties in rats.

[0803] Test Example 3: Pharmacokinetics test in mice

[0804] For a pharmacokinetic study in mice, three male ICR mice weighing 20-30 g were fasted overnight and administered 10 mg / kg orally by gavage. Blood was collected before dosing and at 5, 15, and 30 minutes, as well as 1, 2, 4, 6, 8, and 24 hours after dosing. Blood samples were centrifuged at 6000 g / min for 3 minutes at 2-8°C, and plasma was collected and stored at -20°C. Plasma was collected at each time point and mixed with 10-fold volume of 50% methanol-acetonitrile solution containing an internal standard. The mixture was vortexed for 5 minutes and centrifuged at 4000 rpm at 4°C for 10 minutes. The supernatant was then mixed with 1-fold volume of water, and an appropriate amount of the mixture was analyzed by LC-MS / MS. Key pharmacokinetic parameters were analyzed using a non-compartmental model using WinNonlin 7.0 software.

[0805] Table 3. Results of mouse pharmacokinetic studies

[0806] The experimental results show that the compound of the present invention has good pharmacokinetic properties in mice and has a high oral exposure.

[0807] Test Example 4: Human liver microsome stability test

[0808] The stability test of human liver microsomes was performed by incubating the compound with human liver microsomes in vitro. First, the compound to be tested was prepared into a 10mM stock solution in DMSO solvent, and then the compound was diluted to 0.15mM with acetonitrile. Human liver microsomes (Biovit) were diluted with PBS to form a microsome / buffer solution, and this solution was used to dilute 0.15mM of the compound to form a working solution. The compound concentration in the working solution was 1.0μM and the human liver microsome concentration was 0.5mg / mL. Take a deep well plate, add 30μL of working solution to each well, and then add 30μL of preheated 2mM NADPH solution to start the reaction and incubate at 37°C. At 0, 5, 15, 30, and 60 minutes of incubation, add 300μL of methanol containing internal standard: acetonitrile = 1:1 to the corresponding wells to terminate the reaction. After terminating the reaction with a 1:1 methanol:acetonitrile solution containing an internal standard at the final 60-minute time point, the deep-well plate was vortexed for 10 minutes (600 rpm / min) and then centrifuged for 10 minutes. The supernatant was removed after centrifugation and diluted with purified water in a 1:1 ratio. LC-MS / MS analysis was performed to determine the peak area ratio of the compound to the internal standard at each time point. The peak area ratios of the compound at 5, 15, 30, and 60 minutes were compared with the peak area ratio at 0 minute to calculate the percentage of compound remaining at each time point. T1 / 2 was calculated using Microsoft Excel software.

[0809] Table 4. Human liver microsome stability data

[0810] The stability of the compound in liver microsomes reflects the risk of its metabolic clearance in the body. Experimental results show that the compound of the present invention has good stability in humans.

[0811] Test Example 5: Inhibition test of compounds on cytochrome P450

[0812] Compounds were tested for their inhibitory potential against the cytochrome P450 (CYP450) isoform CYP3A4 (two substrates, midazolam and testosterone). First, the test compound was prepared in DMSO to a 10 mM stock solution, and the CYP3A4 inhibitor ketoconazole was prepared in DMSO to a 10 mM stock solution. The test compound was diluted to 1 mM in acetonitrile, and ketoconazole was diluted to 300 μM. To 720 μL of a 10 mM NADPH solution, 1800 μL of a 12 mM magnesium chloride solution was added, followed by 1080 μL of phosphate buffer (0.1 M, pH 7.4) to prepare an NADPH regeneration solution containing 2 mM NADPH and 6 mM magnesium chloride. The final concentrations of the CYP3A4 substrate midazolam and testosterone in the reaction system were 2 μM and 40 μM, respectively. Prepare human liver microsomal solution at a concentration of 0.2 mg / mL in potassium phosphate buffer on ice. Prepare a microsomal working solution containing testosterone or midazolam at 2x the final concentration using the human liver microsomal solution on ice. Add 100 μL of the microsomal working solution containing testosterone or midazolam to each well. For the corresponding experimental groups, add 2 μL of 1 mM test compound or 300 μM ketoconazole, respectively, in duplicate. Incubate the 96-well assay plate and NADPH solution at 37°C for 10 minutes. Add 98 μL of prewarmed 2 mM NADPH regeneration solution to the assay plate to initiate the reaction. Preincubate the CYP3A4 assay plate using midazolam as a substrate at 37°C for 3 minutes, and the CYP3A4 assay plate using testosterone as a substrate at 37°C for 10 minutes. The reaction was terminated by adding 200 μL of a 1:1 methanol:acetonitrile solution containing an internal standard. After quenching, the plate was shaken on a shaker (IKA, MTS2 / 4) for 10 minutes (600 rpm / min) and then centrifuged for 10 minutes. The supernatant was removed after centrifugation and added with purified water at a 1:1 ratio. LC-MS / MS analysis was performed to determine the peak area ratio of the compound to the internal standard. This peak area ratio was then compared with the peak area ratio of the control inhibitor to calculate the inhibition rate.

[0813] Table 5 Results of CYP450 enzyme inhibition test of test compounds

[0814] The experimental results show that the compounds of the present invention have weak or no inhibitory effect on the CYP3A4 enzyme, and the risk of potential drug-drug interactions is low.

[0815] Test Example 6: Rat CFA Inflammatory Pain Model

[0816] The Complete Freund's Adjuvant (CFA) model is an inflammatory pain model used to evaluate the effectiveness of relieving pain caused by inflammation. After acclimation for 5-7 days, the rats' baseline thermal pain threshold was measured using a radiant heat source (manufactured by Ugo Basile, Italy). The next day, 50 μL of complete Freund's adjuvant was injected into the left sole of the rat's foot to establish the model. On day 4 after model establishment, the animals were orally gavaged with the compound or vehicle. The test sample dose was 20-40 mg / kg, and the control compound, naproxen, was administered at a dose of 20 mg / kg. Thermal pain thresholds were measured 0.5-3 hours after administration using a radiant heat source (manufactured by Ugo Basile, Italy). Data from each group were analyzed using SPSS 16.0 software package, and statistical analysis was performed using one-way ANOVA. Statistical differences between groups were compared, with P < 0.05 considered statistically significant.

[0817] The experimental results are shown in FIG1 . In the CFA rat model, oral administration of the compound of the present invention significantly increased the thermal pain threshold of the animals (p<0.01), demonstrating a good anti-inflammatory pain effect.

[0818] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A compound of formula IA, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug: in, X1 is N or CR5; Ring A is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered aromatic ring; R1 is selected from halogen, deuterium, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; p is selected from 0, 1, 2, 3, 4 or 5; R2 is selected from hydrogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl; The C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; m is selected from 0, 1 or 2; Alternatively, R2 and R2 together with the carbon atom to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; L1 and L2 are each independently absent or selected from R a The replaced C 1-6 Alkylene; Z is selected from NR b , O or S; Ring B is selected from a 5-10 membered heteroaromatic ring; R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl; The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo (=O), hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 5-10 membered heteroaryl substituted with alkyl, -(C=O)NR7R8, C 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO2-C 1-6 alkyl; R4 is selected from halogen, oxo (=O), hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; R5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are connected form a 5- or 6-membered heterocycloalkyl, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3; R a is selected from hydrogen, deuterium (D), halogen, oxo (=O), hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms; R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 alkyl,- OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms, and the S atom may be in the form of an oxide thereof.

2. The compound of formula IA as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, which has the structure shown below: in, X1, Ring A, Ring B, R1, R2, R3, R4, p, n, Z, L1 and L2 have the meanings as defined in claim 1, and R6 has the meaning as defined in R2; Preferably, X1 is N or CR5; Ring A is selected from a 5-6 membered heteroaromatic ring or a 6 membered aromatic ring; R1 is selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; p is selected from 0, 1, 2, 3, 4 or 5; R2 and R6 are each independently selected from hydrogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl; The C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; Alternatively, R2 and R6 together with the carbon atom to which they are attached form a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; L1 and L2 are each independently absent or selected from R a The replaced C 1-6 Alkylene; Z is selected from NR b , O or S; Ring B is selected from a 5-10 membered heteroaromatic ring; When L1 is absent, L2 is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused with a saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl, R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl; The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo (=O), hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 5-10 membered heteroaryl substituted with alkyl, -(C=O)NR7R8, C 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO2-C 1-6 alkyl; When L1 is absent, L2 is methylene, X1 is N, R2 is methoxy, the group for When R3 is selected from When L1 is absent, Z is O, L2 is methylene, X1 is N, R2 is methoxy, and R6 is hydrogen, the group for When R3 is selected from When L1 is absent, Z is O, L2 is methylene, X1 is N, R2 is methoxy, R6 is methyl or methoxy, the group for When R3 is selected from R4 is selected from deuterium (D), halogen, oxo (=O), hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; R5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are connected form a 5- or 6-membered heterocycloalkyl, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3; R a is selected from hydrogen, deuterium (D), halogen, oxo (=O), hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms; R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S, the S atom may be in the form of its oxide; Preferably, X1 is N or CR5; Ring A is selected from a 5-6 membered heteroaromatic ring or a 5-6 membered aromatic ring; R1 is selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; p is selected from 0, 1, 2, 3, 4 or 5; R2 and R6 are each independently selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Heterocycloalkyl; The R2 and R6 are optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1- 6 alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; L1 and L2 are each independently absent or selected from R a The replaced C 1-6 Alkylene; Z is selected from NR b , O or S; Ring B is selected from a 5-10 membered heteroaromatic ring; When L1 is absent, L2 is methylene, and ring B is selected from pyridine, pyridazine, a 5-6 membered heteroaromatic ring fused with a saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl, R3 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkenyl, C 3-7 Heterocycloalkenyl, C 4-10 Heterocycloalkyl, 6-10 membered aryl or 6-10 membered heteroaryl; The R3 is optionally substituted by 1-4 substituents independently selected from the following: halogen, oxo, hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Alkyl, C 1-6 Alkoxy, cyano or halogen substituted C 1-3 Alkyl, C 1-6 Alkyl sulfone, heterocyclic group, heteroaryl group, 1-3 C 1-6 5-10 membered heteroaryl substituted with alkyl, -(C=O)NR7R8, C 3-6 Cycloalkyl, -(C=O)-C 1-6 Alkyl, -(C=O)-C 3-6 Cycloalkyl, C 6-10 Aryl or 1-3 C 1-6 Alkyl-substituted 3-9-membered heterocycloalkyl, -SO2-C 1-6 alkyl; L1 does not exist, L2 is methylene, X1 is N, R2 is methoxy, the group for When R3 is selected from R4 is selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; R5 is selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; R7 and R8 are independently H or C 1-6 Alkyl, or R7 and R8 together with the nitrogen atom to which they are connected form a 5- or 6-membered heterocycloalkyl, wherein the heteroatom is selected from one or more of N, S and O, and the number of the heteroatom is 1, 2 or 3; R a Selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 Alkyl; and the heterocycloalkyl contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 monocyclic rings selected from O and S atoms; R b Selected from hydrogen, deuterium (D), -C 0-6 Alkyl-S(=O)2-C 0-6 Alkyl-, -C 0-6 Alkyl-P(=O)2-C 0-6 Alkyl-, C 1-6 alkyl or 3-6 membered heterocycloalkyl, wherein the C 1-6 The alkyl group is substituted with 0, 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxy, -OC 1-6 Alkyl, -NH2, -NHC 1-6 Alkyl, -OC(=O)C 1-6 Alkyl or -N(C 1-6 Alkyl)C 1-6 and the heterocycloalkyl group contains 0, 1, 2 or 3 N atoms and 0, 1 or 2 atoms selected from O and S atoms, and the S atom may be in the form of an oxide thereof.

3. The compound of formula IA as claimed in claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, One or more of the following conditions are met: a), the ring A is selected from a benzene ring or a 5-6 membered heteroaryl group containing 1, 2 or 3 heteroatoms; b) The heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different; c), the ring A is selected from a benzene ring, pyrrole, pyrazole, imidazole, triazole, furan, oxazole, isoxazole, oxadiazole, thiophene, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine or triazine; d), the ring A is selected from a benzene ring, isoxazole or oxadiazole; e), the ring A is selected from f), wherein R1 is selected from deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; g), wherein R1 is selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen; h), said R1 is selected from deuterium (D), F, Cl, methyl, methoxy, -CHF2, -CF3, -CD3, cyclopropyl; i)、 Selected from j)、 Selected from 4. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: Wherein, X2 is N or CR5; R5 is selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; Preferably, R5 is selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen; Preferably, R5 is selected from deuterium (D), F, Cl, methyl, methoxy, -CHF2, -CF3, -CD3, cyclopropyl; X1, Ring B, R1, R2, R3, R4, R6, p, n, L1 and L2 have the meanings as defined in claim 1.

5. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: Wherein, Ring B, R1, R2, R3, R4, R6, n, L1 and L2 have the meanings as defined in claim 1 R5 is selected from hydrogen, deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy or C 3-7 Cycloalkyl; The R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; Preferably, R5 is selected from deuterium (D), halogen, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl; said R5 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen; Preferably, R5 is selected from deuterium (D), F, Cl, methyl, methoxy, -CHF2, -CF3, -CD3, cyclopropyl;.

6. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: wherein Ring B, R1, R2, R3, R4, L2 and n have the meanings as defined in claim 1; The IV-1 compound satisfies one or more of the following conditions: aa), when L2 is selected from methylene, R2 is selected from methoxy, R1 is selected from methyl, R3 is selected from bb), when L2 is selected from methylene, ring B is selected from pyridine, pyridazine, 5-6 membered heteroaromatic ring fused saturated C 4-6 When heterocycloalkyl, R2 is not tert-butyl, 7. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compound is selected from the following structures: Wherein, the compounds IV-2, IV-3, IV-4, IV-5, IV-6, IV-7, and IV-8 satisfy one or more of the following conditions: cc), Ring B, R1, R2, R3, R4, R6, L1, L2 and n have the meanings as defined in claim 1; Ring D is a 5-8 membered heterocycloalkyl group containing at least one O atom; dd), in the compounds IV-2 and IV-3, R2 and R6 are not hydrogen at the same time; ee), in the compounds IV-2 and IV-3, R2 and R6 are hydrogen; Selected from 8. The compound, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug according to any one of claims 1 to 7, characterized in that: The ring B is selected from a 5-10 membered heteroaromatic ring containing 1, 2, or 3 heteroatoms; The heteroatom is selected from N, O, and S; when there are multiple heteroatoms, the heteroatoms are the same or different; and / or, the ring B is selected from a 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaromatic ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7 Heterocycloalkyl groups may be saturated or unsaturated, but are not aromatic; and / or, the ring B is selected from a 5-membered heteroaromatic ring and C 4-7 Heterocycloalkyl, 6-membered heteroaromatic ring and C 4-6 Heterocycloalkyl; said C 4-6 Heterocycloalkyl or C 4-7 The heterocycloalkyl group is saturated; and / or, the ring B is selected from furan, pyridine, pyridazine, pyrimidine, pyrazine, triazine, thiophene, isoxazole, oxazole, oxadiazole, imidazole, pyrrole, pyrazole, triazole, tetrazole, thiazole, isothiazole, thiadiazole, pyridodihydropyridine, pyridomorpholine, pyridopiperidine, pyridopyrrolidine; and / or, the ring B is selected from pyridine, pyrimidine, pyridazine, pyridodihydropyridine, pyridopiperidine; And / or, the ring B is selected from And / or, the ring B is selected from and / or, Selected from and / or, Selected from 9. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, wherein the compound of formula IA is defined as described in any of the following schemes: Scenario 1: in, Compounds V-1A, V-2A, and V-3A satisfy one or more of the following conditions: ff) R1, R3, R a The definition of is as in claim 1; R2 is not tert-butyl, gg) when R3 is selected from a 4-membered heterocycloalkyl group, the heteroatom is selected from O or S, R1 and R2 are not C 1-6 alkyl; hh) At least one R a is deuterium (D), with a maximum of two R a is deuterium (D); ii) When R1 is methyl, R2 is methoxy, R a When all are hydrogen, R3 is selected from Scenario 2: Wherein, in the compounds of formula V-1, V-2 and V-3, R2 is not tert-butyl, R1, R2, and R3 have the definitions in claim 1; When R3 is selected from a 4-membered heterocycloalkyl group, the heteroatom is selected from O or S, R1 and R2 are not C 1-6 alkyl; When R1 is methyl and R2 is methoxy, R3 is selected from Scenario 3: Wherein, ring D is selected from a 5-6 membered heteroolefin ring; the 5-6 membered heteroolefin ring contains 1 or 2 O; R1 and R3 have the definitions in claim 1; Solution 4: Wherein, R1 is selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 The cycloalkyl group is substituted with 1 to 4 deuterium (D); R2 and R3 have the meanings as defined in claim 1.

10. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, satisfies one or more of the following conditions: 1) R1 is selected from deuterium (D), halogen, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 1-6 Alkoxy; The R1 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; 2) R1 is selected from deuterium (D), F, methyl, -CD3, cyclopropyl, and methoxy; 3) p is 0, 1, 2, 3, 4 or 5; 4) R2 and R6 are each independently selected from hydrogen, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 Heterocycloalkyl; The C 1-3 Alkyl, C 1-3 Alkoxy, C 3-5 Cycloalkyl, C 3-5 The heterocycloalkyl group is optionally substituted with 1-4 substituents independently selected from the group consisting of deuterium (D), halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; 5) R2 and R6 are each independently selected from hydrogen, cyano, methyl, isopropyl, methoxy, cyclopropyl or azetidinyl; The methyl, isopropyl, methoxy, cyclopropyl or azetidinyl group is substituted by 0, 1, 2 or 3 deuterium (D), F, Cl, Br or hydroxyl groups; 6) R2 and R6 are each independently selected from hydrogen, cyano, methyl, methoxy, difluoromethyl, trifluoromethyl, -CHF2, -O-CD3, cyclopropyl, 7) R2 and R6 together with the carbon atom to which they are connected form a 5-8 membered heteroolefin ring containing at least one O atom; the 5-8 membered heteroolefin ring contains There are 1, 2 or 3 heteroatoms; the heteroatoms are selected from O, N, S, P; 8) R2 and R6 together with the carbon atom to which they are attached form 9) L1 does not exist or is selected from R a The replaced C 1-3 Alkylene; 10) L1 is absent or selected from methylene, carbonyl, -CHD-, -CD2-, -CH(CH3)-; 11) L2 does not exist or is selected from R a The replaced C 1-3 Alkylene; 12) L2 is absent or selected from methylene, carbonyl, -CHD-, -CD2-, -CH(CH3)-; 13) Selected from (like )、 14) R3 is selected from cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 4-6 Heterocycloalkyl; said C 1-6 Alkyl, C 1-6 The alkoxy group is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo, hydroxy, C 1-6 Alkoxy, C 1-6 Alkoxy-C 1-6 Alkoxy; the C 4-6 Heterocycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, oxo; 15) R3 is selected from cyano, methyl, ethyl, propyl, isopropyl, oxetanyl, tetrahydropyran, piperazine, 16) R3 is selected from cyano, ethyl, 17) R4 is selected from deuterium (D), halogen, oxo (=O), hydroxyl, CN, C 1-3 Alkyl, C 3-5 Cycloalkyl; The R4 is optionally substituted by 1-4 substituents independently selected from the following: deuterium (D), halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl; when there are multiple substituents, the substituents are the same or different; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; 18) The R4 is selected from deuterium (D) and oxo (═O); n is selected from 0 or 1.

11. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compounds include:

12. The compound of formula IA according to claim 1, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, characterized in that: The compounds include:

13. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: a compound represented by Formula IA as described in claims 1-12, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug; and a pharmaceutically acceptable carrier.

14. The use of a compound of formula IA as described in claims 1 to 12, its tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug, or the use of a pharmaceutical composition as described in claim 13, comprising: Regulation of α5-GABA A Receptors; and / or, prevention and / or treatment of α5-GABA A Receptor-related diseases; And / or, preparing a method for regulating α5-GABA A Receptor, and / or prevention and / or treatment of α5-GABA A Drugs, pharmaceutical compositions or preparations for receptor-related diseases; Preferably, the α5-GABA A Diseases associated with the receptor include: pain, Alzheimer's disease, multi-infarct dementia, or stroke; Preferably, the pain is neuropathic pain, inflammatory pain or cancer pain; Preferably, the pain is selected from headache, facial pain, neck pain, shoulder pain, back pain, chest pain, abdominal pain, low back pain, lower limb pain, muscle and bone pain, vascular pain, gout, arthritis pain, visceral pain, pain caused by infectious diseases, polyostotic pain, sickle cell anemia, autoimmune disease, pain associated with multiple sclerosis or inflammation, chronic pain caused by injury or surgery, nociceptive pain, painful diabetes, trigeminal neuralgia, lumbar or cervical radiculopathy, glossopharyngeal neuralgia, autonomic reflex pain, reflex sympathetic dystrophy, nerve root avulsion, cancer, chemical injury, toxins, nutritional deficiencies, viral or bacterial infections, and pain associated with degenerative osteoarthritis; Preferably, the infectious disease is selected from AIDS or postherpetic neuralgia.

Citation Information

Patent Citations

  • Phthalazine derivatives, and preparation method, pharmaceutical composition and application thereof

    CN106854207A

  • Use of GABAA receptor modulators for treatment of pain

    CN113840610A

  • Triazolopyridazine compound and application thereof

    CN114591352A

  • Triazolopyridazine compound and application thereof

    CN117088885A

  • Triazolopyridazine derivatives for treating anxiety and enhancing cognition

    US6297235B1